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Abstract
Context: In patients treated for prostate cancer, a rising serum prostate-specific
antigen (PSA) level is a first sign of relapse, but imaging is needed to determine the
localization of the recurrence, which may be local, in lymph nodes, and/or
metastatic. With the increasing success rate of earlier salvage therapy, the diagno-
sis has become pertinent when the recurrent PSA level is still very low.
Objective: To systematically review the literature on the role of the existing
imaging techniques in patients with early recurrent prostate cancer.
Evidence acquisition: A systematic literature search across the MEDLINE and
EMBASE databases was conducted in February 2018, searching for original studies
reporting on imaging in a (sub)group of patients with recurrent PSA levels not
higher than 5 ng/ml. This systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)
guidelines. The methodological quality of the studies was assessed using the
Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.
Evidence synthesis: A total of 98 studies were included in this systematic review,
reporting on the role of transrectal ultrasonography (TRUS), computed tomography
(CT), bone scintigraphy (BS), single-photon emission CT, multiparametric magnetic
resonance imaging (mpMRI), whole-body MRI (wbMRI), and positron emission
tomography (PET)-CT/MRI using 18Ffluoro-deoxy-glucose,11C choline,18F (fluoro)
(methyl)choline, 11C acetate, 18F FACBC (fluciclovine) and prostate-specific mem-
A)-brane antigen (PSM* Corresponding author. Di
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early recurrence setting. For the detection of local recurrence, TRUS or mpMRI can
be used; however, at the lowest PSA levels, few data were available, only after
radical prostatectomy, showing a wide range of positivity. TRUS or mpMRI need to
be combined with (PET)-CT to assess distant disease, but new techniques such as
wbMRI, PET-MRI, or PET-CT allow for an all-in-one approach. At recurrent PSA
levels <0.5 ng/ml, detection rates up to 31.3% were reported using 11C choline PET-
CT and up to 65.0% using 68Ga PSMA-11 PET-CT. At recurrent PSA levels<0.2 ng/ml,
detection rates of 68Ga PSMA-11 PET-CT ranged from 11.3% to as high as 58.3%.
Conclusions: Detection rates of different imaging techniques depend on the PSA
level at the time of imaging. Recent advanced imaging techniques may detect the
localization of the recurrence, even when the PSA levels are still very low.
Patient summary: In patients treated for prostate cancer, a rising serum prostate-
specific antigen (PSA) level is a sign of recurrence of the disease. Advanced imaging
techniques may demonstrate the localization of the recurrence, evenwhen the PSA
levels are still very low.
© 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Despite radical treatment for clinically localized prostate
cancer (PCa) with curative intent, early recurrence is
relatively common, occurring in up to 50% of patients
within 10 yr, depending on the type of primary therapy and
stage of the primary tumor [1–3]. PCa recurrence is usually
first suspected when a rise in serum prostate-specific
antigen (PSA) level is observed. The definition of this
biochemical recurrence (BCR) is dependent on the primary
treatment used. After radical prostatectomy (RP), a serum
PSA level over a threshold of 0.2 ng/ml [4], confirmed by two
subsequent consecutive measurements, is considered an
expression of recurrent disease. After radiation therapy
(RT), BCR is defined according to the Phoenix criterion as an
absolute increase in PSA level of 2 ng/ml above nadir (ie, the
lowest post-treatment PSA value) [5,6].
The key question in case of BCR remains whether the PSA
rise is reflective of locally confined recurrence or is caused
by metastatic disease. Correct identification is essential for
further treatment planning because, in local recurrence or
locoregional lymph node metastasis, potentially curative
local treatment may still be possible, whereas in distant
metastasis, watchful waiting or eventually (palliative)
systematic treatment should be considered. Moreover,
there is currently an increasing interest in metastasis-
directed therapies (MDTs) in patients with minimal
metastatic tumor burden (“oligometastatic disease”) in
whom the exact number and localization of these tumoral
lesions should be assessed carefully [7].
PSA testing does not allow for distinguishing between
local, regional, or distant recurrence, although nomograms,
taking into account PSA doubling time (PSAdt), Gleason
score, and TNM stage, may predict the potential localiza-
tion. A slow PSA rise occurring later than 6–12 mo after RP
suggests local recurrence, whereas a fast PSA increase
within a shorter period is suggestive of distant progression.
Current standard practice for suspected recurrent disease
includes imaging by means of transrectal ultrasonography(TRUS), 99mTc-methylene diphosphonate bone scintigraphy
(BS) and abdominopelvic computed tomography (CT).
However, the diagnostic yield of these techniques is low,
and biochemical relapse can precede a detectable morpho-
logical recurrence by a period of months to years.
Conventional imaging often fails to visualize recurrent
disease, and the current practice is that patients undergo
local or systemic treatment based solely on a clinical
probability estimation.
With the increasing success rate of earlier salvage
therapy, the diagnosis of local tumor recurrence at the
earliest possible stage has become pertinent. Salvage RT
after RP has been shown to be most effective, reaching a
durable response when the postoperative PSA is preferably
below 0.5 ng/ml, with an improvement if the PSA is still
below 0.2 ng/ml [4,8]. During early progression at these
low PSA values, the relapse site(s) are expected to be of low
volume. After RP, the recurrent PCa volume is estimated to
be <1 cm3 for PSA levels <3.5 ng/ml [9]. As a result,
recurrences in the early recurrent setting are extremely
difficult to detect with conventional imaging modalities.
Imaging techniques have evolved tremendously in the past
10 yr, with the advent of positron emission tomography
(PET)-CT and multiparametric magnetic resonance imag-
ing (mpMRI) and whole-body MRI (wbMRI), which opened
new perspectives for detecting low-volume metastases at
low PSA levels. Many studies have explored the role of PET,
MRI, CT, etc. in the setting of recurrent PCa, but the mean
PSA values at the time of imaging often varied between
0.2 and 10 or higher, which is actually far above the level at
which the clinician currently wants to know whether the
patient suffers from local or distant recurrence [10–
12]. Many new imaging techniques are currently being
used, but a clear recommendation concerning their uses is
still lacking. The objective of this paper is therefore to
systematically review the literature to determine the role
of imaging in the most challenging and clinically important
cohort, that is, patients at very low rising PSA levels, the
early recurrent setting.
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2.1. Search strategy
This systematic review included studies examining the role
of imaging in the setting of early recurrent PCa. All possible
imaging techniques were eligible for inclusion, such as
TRUS, BS, mpMRI, wbMRI, CT, and PET. In the primary
search, citations were compiled from the electronic MED-
LINE and EMBASE databases, and were searched without
any restriction in publication date up to February 2018. The
following MeSH vocabulary keywords and free texts were
used as search criteria: (“prostate” OR “prostatic”) AND
(“cancer” OR “tumor” OR “carcinoma”) AND (“relapse” OR
“recurrence” OR “treated” OR “recurrent”) AND (“imaging”
OR “PET” OR “tomography” OR “TRUS” OR “ultrasound” OR
“ultrasonography” OR “scintigraphy” OR “scan” OR “CT” OR
“echography” OR “MR” OR “magnetic”). Titles and abstracts
retrieved by the bibliographic search were independently
screened by two authors (P.D.V. and C.S.), and the decision
to include or exclude a study was based on a consensus
agreement. The full text of articles found to be eligible based
on their title and abstract were acquired and read in detail
to determine suitability for inclusion in the study. In the
secondary search, reference lists of the articles of interest
were additionally checked for other relevant records.
Methodological quality of the included papers was assessed
using the Quality Assessment of Diagnostic Accuracy
Studies 2 (QUADAS-2) tool, regarding risk of bias and
applicability concerns in patient selection, index test,
reference standard, and flow and timing [13]. This system-
atic review was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines [14,15].
2.2. Study selection
Articles were included if theywere original research studies
that assessed the role of one or more imaging techniques in
the setting of early recurrent PCa. There is, however, no clear
international definition of what exactly constitutes “early”
recurrent PCa. “Early” can be interpreted as “soon after
initial treatment” and the time interval could be set as
relapse within 2 yr after primary treatment [16,17], but the
problem is that in most studies this time lead is not
reported. “Early” can also be interpreted as “PSA elevation
but still low,” and this appeared to be more useful for the
systematic review because PSA values at BCR are well
reported and in many studies imaging detection rates are
even stratified according to the level of the PSA. Some
authors use a PSA threshold of 3 ng/ml after RP or 5 ng/
ml above nadir after RT to define early recurrent PCa [18,19];
therefore, we arbitrary decided to use a PSA cutoff of 5 ng/
ml as a threshold for inclusion in this systematic review.
Ideally, the patient population in an eligible study consisted
only of patients with PSA levels below the threshold of 5 ng/
ml; however, we also included articles with patients having
higher PSAvalues, provided that the imaging findings in the
subgroups of patients with the lowest PSA levels wereseparately reported, and we included only these subgroup
data for analysis.
Exclusion criteria consisted of case reports, editorials,
(systematic) review articles, animal and phantom studies,
conference proceedings, studies in a language other than
English, and studies reporting initial results from novel or
rarely used PET tracers such as CuCl, bombesin, etc.
Although we would have preferred to exclude also all
studies reporting only positivity rates or studies without
any standard of reference, thus providing insufficient data
to construct 2  2 contingency tables to calculate sensitiv-
ity or specificity, we were forced to include them because
this appeared to be the case in almost all studies on PET-CT
in the early recurrence setting published in the recent
years.
2.3. Data extraction
The following common characteristics were extracted from
each study: first author name, institution, journal reference,
publication year, imaging modality, data about imaging
technique such as scan sequences of mpMRI or tracer used
in PET-CT, total number of patients in the study, primary
therapy (RT, RP, or mixed), location of the recurrence (local
recurrence, lymph nodes, bone metastases, or soft tissue
lesions), standard of reference (histology, clinical and
imaging follow-up, TRUS biopsy, lymph node dissection,
etc.), and study design (prospective or retrospective).
Detection rates of each imaging modality were stratified
according to the following PSA groups: 0.2, 0.5, 1, 2,
5, 0.5–1, 1–2, and 2–5 ng/ml. When the positivity rates
and/or sensitivity and specificity for these subgroups were
not mentioned in the article, wherever possible
2  2 contingency tables were obtained from the provided
data and detection rates were manually calculated for each
subgroup. If a study reported multiple imaging modalities
(eg, PET-CTwith different tracers or comparison between BS
and MRI), the data were extracted for each imaging
modality separately.
3. Evidence synthesis
3.1. Characteristics of the included studies
The initial screening resulted in 836 records. After review-
ing the title and abstract of each study, 603 irrelevant
records were excluded. Another 159 records were excluded
after reading the full-text articles. Twenty-four additional
records were retrieved by screening the references, result-
ing in 98 articles that were eventually included in this
systematic review. A flowchart showing the search strategy
and number of papers identified and included or excluded
at each stage is presented in Figure 1. Basic details of the
studies included in this systematic review are listed in
Supplementary Table 1.
The majority of the studies (78/98, 79.6%) report on the
role of one single imaging modality in the setting of early
recurrent PCa, but 20 studies (20.4%) compare or combine
two or more imaging modalities. For example, mpMRI was
[(Fig._1)TD$FIG]
Fig. 1 – Flow chart depicting the search strategy used to select relevant studies. The literature search was done according to the 2009 guidelines of the
PRISMA. PET = positron emission tomography; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis.
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to detect local recurrence and the latter aiming to detect
distant disease. Other studies mixed similar imaging
techniques within one patient cohort, such as PET-CT and
PET-MRI with the same diagnostic tracer (four studies), or
mixed similar tracers (eg, 18F choline and 11C choline) in PET-
CT. Head-to-head comparisons of different imaging modali-
ties or PET tracers were relatively sparse and include small
numbers of patients. Five (5.1%) papers reported on the
performance of TRUS in the early recurrence setting, three
(3.1%)on theperformanceofCT, three (3.1%)onBS, four (4.1%)
on single-photon emission CT (SPECT) with 111In-capromab
pendetide (Prostascint; Cytogen, Princeton, NJ, USA), 10
(10.2%) onmpMRI, and four (4.1%) onwbMRI. PET-CTwas the
most commonly studied imaging modality, being used in
80studies (81.6%), ofwhich four (5.0%)with18F fluoro-deoxy-
glucose (FDG), 10 (12.5%) with 11C acetate, 25 (31.3%) with
11C choline,12 (15.0%) with 18F fluorocholine,11 (13.8%) with18F choline, and 21 (26.3%) with 68Ga prostate-specific
membrane antigen (PSMA).
In six studies (6.3%), PET-MRI was used. Sample sizes in
the studies varied widely, from 11 to 3203 total patients in a
study, although not all these patients belonged to the low
PSA subgroups. The majority of the included studies were
single-center studies. Our bibliographic search revealed
that some groups have published multiple studies intro-
ducing the risk of data duplication.
Ninety-five studies (96.9%) reported the performance of
an imaging technique in a (sub)group of patients with BCR
at a PSA level of not higher than 1 ng/ml. Forty-eight papers
(49.0%) reported the detection rates in a (sub)group of
patients with PSA not higher than 0.5 ng/ml. Fifteen papers
(15.3%) even reported the performance of an imaging
modality in a (sub)group of patients with rising PSA levels
not higher than 0.2 ng/ml (316 patients in total; Tables 1–4
and Supplementary Table 2).
Table 1 – Studies reporting on imaging in early recurrent prostate cancer at PSA level 0.2 ng/ml
Author (year) Imaging type Tracer Primary therapy Aim detection Standard of reference N Positivity
rate
Kotzerke et al. (2002) [37] TRUS RP RP Local recurrence TRUS biopsy, clinical and imaging
follow-up
1 0.0%
Cimitan et al. (2006) [48] BS Mixed 85 RP, 21 RT, 21 ADT Bone Clinical and imaging follow-up 1 0.0%
Cimitan et al. (2015) [90] CT Mixed 85 RP, 21 RT, 21 ADT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up 1 0.0%
Liauw et al. (2013) [53] mpMRI T2, DWI, and DCE at 1.5 and
3.0 T with ERC
RP RP Local recurrence None 25 8.0%
Sodee et al. (1996) [109] SPECT 111In-capromab pendetide
(Prostascint)
RP RP Local, lymph nodes, bone, and
soft tissues
None 1 100.0%
Reinfelder et al. (2017) [133] SPECT-CT 99mTc PSMA Mixed RP, RT, or ADT Local, lymph nodes, bone, and
soft tissues
None 1 0.0%
de Jong et al. (2003) [68] PET 11C choline Mixed 20 RP, 16 RT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
11 0.0%
Cimitan et al. (2006) [48] PET-CT 18F fluorocholine Mixed 85 RP, 21 RT, 21 ADT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up 3 0.0%
Meredith et al. (2016) [34] PET-CT 68Ga PSMA-11 Mixed RP Local, lymph nodes, bone, and
soft tissues
None 124 11.3%
Derlin et al. (2018) [125] PET-CT 68Ga PSMA-11 RP RP  RT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
9 22.2%
Sachpekidis et al. (2016) [119] PET-CT 68Ga PSMA-11 RP RP  RT Local, lymph nodes, bone, and
soft tissues
None 4 25.0%
Schmuck et al. (2017) [126] PET-CT 68Ga PSMA-11 Mixed 209 RP, 31 RT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology in a minority of patients
(n = 112)
18 38.9%
Afshar-Oromieh et al. (2017) [112] PET-CT 68Ga PSMA-11 Mixed 828 RP, 600 RT Local, lymph nodes, bone, and
soft tissues
None 69 46.4%
Afshar-Oromieh et al. (2015) [111] PET-CT 68Ga PSMA-11 Mixed 226 RP  RT, 177 RT Local, lymph nodes, bone, and
soft tissues
Histology in a minority of patients
(n = 42)
17 47.1%
Gupta et al. (2017) [33] PET-CT 68Ga PSMA-11 Mixed 75 RP, 70 RT Local, lymph nodes, bone, soft
tissues
None 12 41.7% total,
45.4% after
RP, 0%
after RT
Hope et al. (2017) [123] PET-CT or PET-MRI 68Ga PSMA-11 Mixed 43 RP, 41 RT, 9 other Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up 12 58.3%
Kranzbuhler et al. (2018) [124] PET-MRI 68Ga PSMA-11 RP RP Local, lymph nodes, bone, soft
tissues
None 9 44.4%
ADT = androgen deprivation therapy; BS = bone scintigraphy; CT = computed tomography; DCE = dynamic contrast-enhanced imaging; DWI = diffusion-weighted imaging; ERC = endorectal coil; mpMRI = multiparametric
MRI; MRI = magnetic resonance imaging; PET = positron emission tomography; PSA = prostate-specific antigen; PSMA = prostate-specific membrane antigen; RP = radical prostatectomy; RT = radiotherapy; SPECT = single-
photon emission CT; TRUS = transrectal ultrasonography.
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Table 2 – Studies reporting on imaging in early recurrent prostate cancer at PSA level 0.5 ng/ml
Author (year) Imaging type Tracer Primary therapy Aim detection Standard of reference N Positivity
rate
Kotzerke et al. (2002) [37] TRUS RP Local recurrence TRUS biopsy, clinical and imaging
follow-up
1 0.0%
Connolly et al. (1996) [35] TRUS RP Local recurrence TRUS biopsy 32 28.1%
Scattoni et al. (2003) [40] TRUS RP Local recurrence TRUS biopsy in all patients 34 73.0%
Cimitan et al. (2006) [48] BS Mixed 85 RP, 21 RT, 21 ADT Bone Clinical and imaging follow-up 11 10.0%
Cimitan et al. (2006) [48] CT Mixed 85 RP, 21 RT, 21 ADT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up 8 25.0%
Vadi et al. (2017) [26] wbMRI DCE RP Local, lymph nodes, bone, and
soft tissues
TRUS or CT biopsy 1 0.0%
Counago et al. (2015) [52] mpMRI T2, T1, DWI, DCE at 3 T RP Local recurrence None 31 12.9%
Liauw et al. (2013) [53] mpMRI T2, DWI, and DCE at
1.5 and 3.0 T with ERC
RP Local recurrence None 60 17.0%
Linder et al. (2014) [39] mpMRI T2, DCE at 1.5 T with
ERC
RP Local recurrence TRUS biopsy in all patients 53 94.0%
Raj et al. (2002) [107] SPECT 111In-capromab
pendetide (Prostascint)
RP Local, lymph nodes, bone, and
soft tissues
Histology in a minority of
patients
79 68.4%
Sodee et al. (1996) [109] SPECT 111In-capromab
pendetide (Prostascint)
RP Local, lymph nodes, bone, and
soft tissues
None 2 100.0%
Reinfelder et al. (2017) [133] SPECT-CT 99mTc PSMA Mixed RP, RT, or ADT Local, lymph nodes, bone, and
soft tissues
None 4 25.0%
Oyama et al. (2003) [63] PET-CT 18F FDG Mixed 30 RP, 16 RT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
7 0.0%
de Jong et al. (2003) [68] PET-CT 11C choline Mixed 20 RP, 16 RT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
12 0.0%
Giovacchini et al. (2010) [75] PET-CT 11C choline RP Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
51 7.8%
Souvatzoglou et al. (2011) [85] PET-CT 11C choline RP Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up 20 15.0%
Mamede et al. (2013) [79] PET-CT 11C choline RP Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
71 21.1%
Mitchell et al. (2013) [80] PET-CT 11C choline Mixed 127 RP, 41 RT, 8 other Local, lymph nodes, bone, and
soft tissues
Histology in a minority of
patients (n = 73), clinical and
imaging follow-up (n = 103)
16 31.3%
Rinnab et al. (2007) [82] PET-CT 11C choline Mixed 40 RP, 3 RT, 7 BT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
2 50.0%
Vadi et al. (2017) [26] PET-CT 18F fluorocholine RP Local, lymph nodes, bone, and
soft tissues
TRUS or CT biopsy 1 0.0%
Kwee et al. (2012) [94] PET-CT 18F fluorocholine Mixed 28 RP, 13 RT, 9 BT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up 12 8.3%
Morigi et al. (2015) [96] PET-CT 18F fluorocholine Mixed 22 RP, 4 RT, 22 RP + RT Local, lymph nodes, bone, and
soft tissues
histology in a minority of
patients (n = 9)
16 12.5%
Cimitan et al. (2006) [48] PET-CT 18F fluorocholine Mixed 85 RP, 21 RT, 21 ADT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up 20 20.0%
Marzola et al. (2013) [95] PET-CT 18F fluorocholine RP with or without
adjuvant treatment
Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
64 28.1%
Beheshti et al. (2012) [138] PET-CT 18F fluorocholine Mixed 116 RP, 48 RT, 60 RP
and RT, 26 ADT only
Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
NA 33.0%
Dusing et al. (2014) [101] PET-CT 11C acetate Mixed 35 RP, 38 RT, 21 BT,
7 RP + RT, 19 BT + RT
Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
13 23.1%
Oyama et al. (2003) [63] PET-CT 11C acetate Mixed 30 RP, 16 RT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
7 28.6%
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Table 2 (Continued )
Author (year) Imaging type Tracer Primary therapy Aim detection Standard of reference N Positivity
rate
Almeida et al. (2017) [100] PET-CT 11C acetate Mixed 213 RP, 251 RT,
229 RP + RT, 38 other
Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology in a minority of
patients (n = 105)
62 74.0%
Mena et al. (2018) [129] PET-CT 18F DCFBC Mixed 50 RP, 9 RT, 9 RP + RT Local, lymph nodes, bone, and
soft tissues
Histology in a minority of
patients (n = 18)
13 15.4%
Dietlein et al. (2017) [115] PET-CT 18F DCFPyL RP Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up NA 13.0%
Dietlein et al. (2017) [115] PET-CT 68Ga PSMA-11 RP Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up NA 11.0%
Sanli et al. (2017) [120] PET-CT 68Ga PSMA-11 RP Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up 10 20.0%
Sachpekidis et al. (2016) [119] PET-CT 68Ga PSMA-11 RP  RT Local, lymph nodes, bone, and
soft tissues
None 8 37.5%
Calais et al. (2018) [113] PET-CT 68Ga PSMA-11 RP Local, lymph nodes, bone, and
soft tissues
Histology, clinical and imaging
follow-up in minority of patients
153 40.5%
Afshar-Oromieh et al. (2017) [112] PET-CT 68Ga PSMA-11 Mixed 828 RP, 600 RT Local, lymph nodes, bone, and
soft tissues
None 177 46.3%
Afshar-Oromieh et al. (2015) [111] PET-CT 68Ga PSMA-11 Mixed 226 RP  RT, 177 RT Local, lymph nodes, bone, and
soft tissues
Histology in a minority of
patients (n = 42)
27 48.1%
Morigi et al. (2015) [96] PET-CT 68Ga PSMA-11 Mixed 22 RP, 4 RT, 22 RP + RT Local, lymph nodes, bone, and
soft tissues
Histology in a minority of
patients (n = 9)
16 50.0%
Lengana et al. (2018) [117] PET-CT 68Ga PSMA-11 Mixed 28 RP, 21 RP + RT, 12 RT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up 11 55.0%
Rauscher et al. (2018) [118] PET-CT 68Ga PSMA-11 RP Local, lymph nodes, bone, and
soft tissues
Histology in a minority of
patients
134 55.0%
Eiber et al. (2015) [116] PET-CT 68Ga PSMA-11 RP Local, lymph nodes, bone, and
soft tissues
None 19 58.0%
Meredith Get al (2016) [34] PET-CT 68Ga PSMA-11 Mixed 425 RP, 107 RT Local, lymph nodes, bone, and
soft tissues
None 206 total,
203 RP,
3 RT
17.5% total,
17.2% RP,
33.3% RT
Gupta et al. (2017) [33] PET-CT 68Ga PSMA-11 Mixed 75 RP, 70 RT Local, lymph nodes, bone, and
soft tissues
None 28 (27 RP,
1 RT)
42.9% total,
44.4% RP,
0% RT
Schmuck et al. (2017) [126] PET-CT 68Ga PSMA-11 Mixed 209 RP, 31 RT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology in a minority of
patients (n = 112)
52 50.0%
Berliner et al. (2017) [127] PET-CT 68Ga PSMA-11 RP Local, lymph nodes, bone, and
soft tissues
Histology in a minority of
patients (n = 2)
33 51.5%
Derlin et al. (2018) [125] PET-CT 68Ga PSMA-11 RP  RT Local, lymph nodes, bone, and
soft tissues
Clinical and imaging follow-up,
histology
24 20.8%
Kranzbuhler et al. (2018) [124] PET-MRI 68Ga PSMA-11 RP Local, lymph nodes, bone, soft
tissues
None 20 60.0%
Hope et al. (2017) [123] PET-CT or PET-MRI 68Ga PSMA-11 Mixed 43 RP, 41 RT, 9 other Local, lymph nodes, bone, soft
tissues
Clinical and imaging follow-up 26 61.5%
Grubmuller et al. (2018) [122] PET-CT or PET-MRI 68Ga PSMA-11 RP Local, lymph nodes, bone, soft
tissues
Clinical and imaging follow-up,
histology
NA 65.0%
ADT = androgen deprivation therapy; BS = bone scintigraphy; BT = brachytherapy; CT = computed tomography; DCE = dynamic contrast-enhanced imaging; DWI = diffusion-weighted imaging; ERC = endorectal coil;
FDG = fluoro-deoxy-glucose; mpMRI = multiparametric MRI; MRI = magnetic resonance imaging; NA = not available; PET = positron emission tomography; PSA = prostate-specific antigen; PSMA = prostate-specific
membrane antigen; RP = radical prostatectomy; RT = radiotherapy; SPECT = single-photon emission CT; TRUS = transrectal ultrasonography; wbMRI = whole-body MRI.
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Table 3 – Studies reporting on imaging in early recurrent prostate cancer at PSA level 1.0 ng/ml
Author (year) Imaging type Tracer Primary therapy Aim detection Standard of reference N PSA at
imaging
Positivity
rate
Sensitivity Specificity
Connolly et al. (1996) [35] TRUS RP Local recurrence TRUS biopsy 54 1 37.0% NA NA
Scattoni et al. (2003) [40] TRUS RP Local recurrence TRUS biopsy in all patients 68 1 66.2% NA NA
Kotzerke et al. (2002) [37] TRUS RP Local recurrence TRUS biopsy, clinical and
imaging follow-up
3 1 66.7% 100.0% 50.0%
Su et al. (2017) [61] BS Mixed 30 RP, 16 RT Bone Clinical and imaging
follow-up
10 1 10.0% NA NA
Cimitan et al. (2006) [48] BS Mixed 85 RP, 21 RT, 21 ADT Bone Clinical and imaging
follow-up
16 1 18.8% NA NA
Odewole et al. (2016) [49] CT Mixed 7 RP, 5 RT, 41 other Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up 5 yr
8 1 12.5% NA NA
Cimitan et al. (2006) [48] CT Mixed 85 RP, 21 RT, 21 ADT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
10 1 20.0% NA NA
Su et al. (2017) [61] wbMRI T2 Mixed 30 RP, 16 RT Lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
10 1 10.0% NA NA
Vadi et al. (2017) [26] wbMRI DCE RP Local, lymph nodes,
bone, and soft
tissues
TRUS or CT biopsy 4 1 25.0% NA NA
Liauw et al. (2013) [53] mpMRI T2, DWI, and DCE
at 1.5 and 3.0 T
with ERC
RP Local recurrence None 67 <0.72 19.0% NA NA
Vees et al. (2007) [58] mpMRI NA RP Local recurrence Clinical and imaging
follow-up
18 1 85.0% NA NA
Kitajima et al. (2014) [21] mpMRI T2, T1, DWI, and
DCE at 1.5 and 3.0 T
with ERC
RP Local recurrence Clinical and imaging
follow-up
7 1 NA 80.0% NA
Petronis et al. (1998) [108] SPECT 111In-capromab
pendetide
(Prostascint)
Mixed 48 RP, 2 RT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
15 1 60.0% NA NA
Raj et al. (2002) [107] SPECT 111In-capromab
pendetide
(Prostascint)
RP Local, lymph nodes,
bone, and soft
tissues
Histology in a minority
of patients
136 1 68.4% NA NA
Sodee et al. (1996) [109] SPECT 111In-capromab
pendetide
(Prostascint)
RP Local, lymph nodes,
bone, and soft
tissues
None 4 1 75.0% NA NA
Elgamal et al. (1998) [106] SPECT 111In-capromab
pendetide
(Prostascint)
Mixed 58 RP, 81 RT and/or ADT Local, lymph nodes,
bone, and soft
tissues
Histology in a minority
of patients (n = 33)
38 1 Total 79%,
local 37%
NA NA
Su et al. (2017) [61] SPECT-CT 99mTc PSMA Mixed 30 RP, 16 RT Lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
10 1 30.0% NA NA
Reinfelder et al. (2017) [133] SPECT-CT 99mTc PSMA Mixed RP, RT, or ADT Lymph nodes,
bone, and soft
tissues
None 11 1 36.4% NA NA
Oyama et al. (2003) [63] PET-CT 18F FDG Mixed 30 RP, 16 RT Local, lymph nodes,
bone and soft
tissues
Clinical and imaging
follow-up, histology
14 1 0.0% NA NA
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Table 3 (Continued )
Author (year) Imaging type Tracer Primary therapy Aim detection Standard of reference N PSA at
imaging
Positivity
rate
Sensitivity Specificity
Richter et al. (2010) [64] PET-CT 18F FDG Mixed 49 RP, 24 RT Local, lymph nodes,
bone and soft
tissues
Clinical and imaging
follow-up, histology
15 1 13.3% 15.4% 100.0%
de Jong et al. (2003) [68] PET-CT 11C choline Mixed 20 RP, 16 RT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
16 1 0.0% NA NA
Richter et al. (2010) [64] PET-CT 11C choline Mixed 49 RP, 24 RT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
15 1 6.7% 7.7% 100.0%
Nanni et al. (2016) [81] PET-CT 11C choline RP  RT or HT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
28 1 14.3% 14.0% NA
Souvatzoglou et al. (2011) [85] PET-CT 11C choline RP Local or lymph
nodes
Clinical and imaging
follow-up
30 1 16.7% NA NA
Castellucci et al. (2009) [70] PET-CT 11C choline RP Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
51 1 19.0% NA NA
Giovacchini et al. (2010) [75] PET-CT 11C choline RP Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
141 1 19.1% NA NA
Bertagna et al. (2011) [69] PET-CT 11C choline Mixed 114 RP, 26 RP
+ RT, 70 RT
Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
NA <0.81 20.0% NA NA
Castellucci et al. (2014) [72] PET-CT 11C choline RP Local, lymph nodes,
bone, and soft
tissues
TRUS biopsy, surgical
lymphadenectomy, other
imaging or FU >12 mo
291 <1.05 23.0% NA NA
Rybalov et al. (2013) [84] PET-CT 11C choline Mixed 61 RP, 124 RT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
25 1 24.0% NA NA
Krause et al. (2008) [78] PET-CT 11C choline Mixed 42 RP, 21
RT and other
Local or lymph
nodes
Clinical and imaging
follow-up, histology
22 1 36.4% NA NA
Rinnab et al. (2007) [82] PET-CT 11C choline Mixed 40 RP, 3 RT, 7 BT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
5 1 40.0% NA NA
Gomez-de la Fuente et al. (2018) [76] PET-CT 11C choline Mixed 46 RP, 3
EBRT, 1 HT
Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
50 1 42.0% 77.8% 65.9%
Mitchell et al. (2013) [80] PET-CT 11C choline Mixed 127 RP,
41 RT, 8 other
Local, lymph nodes,
bone, and soft
tissues
Histology in a minority of
patients (n = 73), clinical
and imaging follow-up
(n = 103)
34 1 44.1% NA NA
Passoni et al. (2014) [43] PET-CT 11C choline RP Lymph nodes Lymph node dissection in
all patients
29 1 100.0% NA NA
Rinnab et al. (2008) [22] PET-CT 11C choline RP  RT and/or HT Lymph nodes Lymph node dissection in
all patients
1 1 100.0% 100.0% 0.0%
Kitajima et al. (2014) [21] PET-CT 11C choline RP Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
7 1 NA 20.0% local,
100% distant
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Table 3 (Continued )
Author (year) Imaging type Tracer Primary therapy Aim detection Standard of reference N PSA at
imaging
Positivity
rate
Sensitivity Specificity
Pelosi et al. (2008) [97] PET-CT 18F choline RP Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
20 1 20.0% NA NA
Schillaci (2012) [99] PET-CT 18F choline RP Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
10 1 20.0% NA NA
Cimitan et al. (2015) [90] PET-CT 18F choline Mixed 353 RP, 167 RP + RT,
152 RT, 121 ADT, 207 other
Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
211 1 31.3% NA NA
Vees et al. (2007) [58] PET-CT 18F choline RP Local or lymph
nodes
Clinical and imaging
follow-up
11 1 45.5% NA NA
Detti et al. (2013) [91] PET-CT 18F choline Mixed 126 RP, 40 RT, 4 ADT
with or without
adjuvant therapy
Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
51 1 49.0% NA NA
Chiaravalloti et al. (2016) [89] PET-CT 18F choline RP Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
16 1 50.0% NA NA
Osmonov et al. (2014) [42] PET-CT 18F choline Mixed 10 RT, 39 RP,
 adjuvant treatment
Lymph nodes Lymph node dissection in
all patients
10 1 70.0% 0.0% 22.2%
Gauvin et al. (2017) [92] PET-CT 18F fluoro(methyl)
choline
Mixed 33 RP, 26 RT, 1 HIFU Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
NA 1 0.0% NA NA
Cimitan et al. (2006) [48] PET-CT 18F fluoro(methyl)
choline
Mixed 85 RP, 21 RT, 21 ADT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
30 1 16.7% NA NA
Vadi et al. (2017) [26] PET-CT 18F fluoro(methyl)
choline
RP Local, lymph nodes,
bone, and soft
tissues
TRUS or CT biopsy 4 1 25.0% NA NA
Marzola et al. (2013) [95] PET-CT 18F fluoro(methyl)
choline
RP with or without
adjuvant treatment
Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
99 1 32.3% NA NA
Rodado-Marina et al. (2015) [98] PET-CT 18F fluoro(methyl)
choline
Mixed 130 RP, 103 other Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
55 1 38.2% NA NA
Buchegger et al. (2014) [19] PET-CT 18F fluoro(methyl)
choline
Mixed 7 RP, 7 RT, 9 RP
and salvage RT
Local, lymph nodes,
bone, soft tissues
Clinical and imaging
follow-up
6 1 50.0% NA NA
Simone et al. (2015) [88] PET-CT 18F fluoro(methyl)
choline
RP Local, lymph nodes,
bone, and soft
tissues
TRUS biopsy, salvage
lymph node dissection
when PET positive, bone
biopsy
146 0.2–1 76.0% 78.9% 76.9%
Esch et al. (2017) [102] PET-CT 11C acetate Mixed 97 RP, 6 RT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
40 1 15.0% NA NA
Oyama et al. (2003) [63] PET-CT 11C acetate Mixed 30 RP, 16 RT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
14 1 28.6% NA NA
Dusing et al. (2014) [101] PET-CT 11C acetate Mixed 35 RP, 38 RT, 21
BT, 7 RP + RT,
19 BT + RT
Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
24 0.59 33.3% NA NA
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Table 3 (Continued )
Author (year) Imaging type Tracer Primary therapy Aim detection Standard of reference N PSA at
imaging
Positivity
rate
Sensitivity Specificity
Albrecht et al. (2007) [51] PET-CT 11C acetate RP Local recurrence PSA decrease after RT of RP
fossa
11 <0.8 50.0% NA NA
Buchegger et al. (2014) [19] PET-CT 11C acetate Mixed 7 RP, 7 RT, 9
RP and salvage RT
Local, lymph nodes,
bone, soft tissues
Clinical and imaging
follow-up
6 1 50.0% NA NA
Vees et al. (2007) [58] PET-CT 11C acetate RP Local or lymph
nodes
Clinical and imaging
follow-up
11 1 63.6% NA NA
Almeida et al. (2017) [100] PET-CT 11C acetate Mixed 213 RP, 251 RT,
229 RP + RT, 38 other
Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology in a
minority of patients
(n = 105)
161 1 73.9% NA NA
Mena et al. (2018) [129] PET-CT 18F DCFBC Mixed 50 RP, 9 RT, 9 RP + RT Local, lymph nodes,
bone, and soft
tissues
Histology in a minority of
patients (n = 18)
26 1 30.8% NA NA
Nanni et al. (2016) [81] PET-CT 18F FACBC
(fluciclovine)
RP  RT or HT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
28 1 21.4% 21.0% NA
Odewole et al. (2016) [49] PET-CT 18F FACBC
(fluciclovine)
Mixed 7 RP, 5 RT, 41 other Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up 5 yr
8 1 37.5% NA NA
Bach-Gansmo et al. (2017) [104] PET-CT 18F FACBC
(fluciclovine)
Mixed 130 RP, 76 RT, 62 RP
+ other, 266 RT + other
Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology in a
minority of patients
(n = 136)
128 <0.79 41.4% NA NA
Derlin et al. (2018) [125] PET-CT 68Ga PSMA-11 RP  RT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology
38 1 18.4% NA NA
Sanli et al. (2017) [120] PET-CT 68Ga PSMA-11 RP Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up
14 1 21.4% NA NA
Sachpekidis et al. (2016) [119] PET-CT 68Ga PSMA-11 RP  RT Local, lymph nodes,
bone, and soft
tissues
None 11 1 36.4% NA NA
Verburg et al. (2016) [121] PET-CT 68Ga PSMA-11 Mixed 99 RP  RT, 45 RT, 29 other Local, lymph nodes,
bone, and soft
tissues
Histology in a minority of
patients (n = 18), follow-up
in a minority of patients
(n = 7)
27 1 44.4% NA NA
Calais et al. (2018) [113] PET-CT 68Ga PSMA-11 RP Local, lymph nodes,
bone, and soft
tissues
Histology, clinical and
imaging follow-up in a
minority of patients
270 1 49.0% NA NA
Berliner et al. (2017) [127] PET-CT 68Ga PSMA-11 RP Local, lymph nodes,
bone, and soft
tissues
Histology in a minority of
patients (n = 2)
44 1 52.3% NA NA
Afshar-Oromieh et al. (2015) [111] PET-CT 68Ga PSMA-11 Mixed 226 RP  RT, 177 RT Local, lymph nodes,
bone, and soft
tissues
Histology in a minority of
patients (n = 42)
51 1 52.9% NA NA
Schmuck et al. (2017) [126] PET-CT 68Ga PSMA-11 Mixed 209 RP, 31 RT Local, lymph nodes,
bone, and soft
tissues
Clinical and imaging
follow-up, histology in a
minority of patients
(n = 112)
81 1 53.1% NA NA
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early PCa recurrence varied between the studies. In about
half of the papers (48.0%), study cohorts were a very
heterogeneous mixture of patients who were initially
treated with RP and/or RT and/or hormonal therapy and/
or other therapies or combinations. In 49 studies (50.0%), all
patients were initially treated with RP (with our without
adjuvant RT and/or hormonal therapy), and in only three
studies (3.1%), exclusively patients initially treated with
primary RT were included.
Some imaging techniques such as SPECT with 111In-
capromab pendetide (Prostascint) were mainly used in the
past andmay have currently disappeared, while others such
as PET-CT with tracers 11C choline and 68Ga PSMA were
developed relatively recently, but a very high number of
publications show their use in the early recurrent setting.
3.2. Methodological quality
Major bias regarding patient selection, index test, reference
standard, flow, and timing was found in almost all the
included studies. The interpretation of the index test results
was considered at a high risk of bias if the study was
retrospective. This was the case in 54 studies (55.1%). The
interpretation of the reference standardwas considered at a
high risk of bias when the physician who determined the
reference standard was aware of the results of the index
test. This was inevitably the case in all the studies in which
the standard of reference to validate the imaging resultswas
clinical and biochemical follow-up or comparison with
findings on other imaging modalities or confirmatory
biopsy of suspicious lesions. Since follow-up imaging is
interpreted with knowledge of the index test imaging
result, and because a confirmatory biopsy of a suspicious
lesion is usually based on and targeted to the lesion,
knowledge of the results of the imaging test is inevitable
and therefore the risk of bias in the execution and
interpretation of the reference standard was judged high
in most studies. Only in studies in which all patients
underwent TRUS biopsy to confirm or exclude local
recurrence and in studies in which all patients underwent
systematic pelvic lymph node dissection to evaluate lymph
node metastases, the reference standards could be consid-
ered as more robust.
In a few studies, there were concerns of applicability,
that is, the included patients and setting did not match the
review question for the systematic review, for example,
studies that enrolled only patientswith previously excluded
local recurrence or bone metastases who were referred for
detection of lymph node metastases followed by pelvic
lymph node dissection. Detailed results of the QUADAS-2
quality evaluation are demonstrated in Supplementary
Table 3.
3.3. General findings
3.3.1. Imaging modalities directed to the site of recurrence
The clinical role of an imaging technique in BCR varies
depending on the type of imaging. TRUS andmpMRI are, for
Table 4 – Studies reporting on imaging in early recurrent prostate cancer at PSA level 2.0 ng/ml
Author and year Imaging
type
Tracer Primary therapy Aim detection Standard of reference N Positivity rate Sensitivity Specificity
Deliveliotis et al. (2007) [36] TRUS RP Local recurrence TRUS biopsy 13 30.8% 100% (95% CI
43–100)
90% (95% CI
59–98)
Leventis et al. (2001) [38] TRUS RP Local recurrence TRUS biopsy in all patients 51 31.4% 69.0% 74.0%
Connolly et al. (1996) [35] TRUS RP Local recurrence TRUS biopsy 68 42.6% NA NA
Scattoni et al. (2003) [40] TRUS RP Local recurrence TRUS biopsy in all patients 96 64.6% 69% (54–81) 63% (47–77)
Kotzerke et al. (2002) [37] TRUS RP Local recurrence TRUS biopsy, clinical and
imaging follow-up
8 75.0% 100.0% 66.7%
Cimitan et al. (2006) [48] BS Mixed 85 RP, 21 RT, 21 ADT Bone Clinical and imaging
follow = up
23 21.7% NA NA
Odewole et al. (2016) [49] CT Mixed 7 RP, 5 RT, 41 other Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up
5 yr
17 5.9% NA NA
Cimitan et al. (2006) [48] CT Mixed 85 RP, 21 RT, 21 ADT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up 13 30.8% NA NA
Vadi et al. (2017) [26] wbMRI DCE RP Local, lymph nodes,
bone, and soft tissues
TRUS or CT biopsy 9 33.3% NA NA
Wieder et al. (2017) [86] wbMRI RP Local, lymph nodes,
bone
Clinical and imaging follow-up,
histology
15 3/15 local rec,
20/120 LN,
11/120 bone
66.6% local rec,
64.7% LN, 66.7%
bone
91.7% local,
91.4% LN,
95.5% bone
Panebianco et al. (2013) [55] mpMRI T2, DCE, DWI at 3.0 T RP Local recurrence TRUS biopsy or PSA decrease
after RT
126 NA 93–98% 89–95%
Kitajima et al. (2014) [21] mpMRI T2, T1, DWI, and DCE at
1.5 and 3.0 T with ERC
RP Local recurrence Clinical and imaging follow-up 37 NA 85.0% NA
Counago et al. (2015) [52] mpMRI T2, T1, DWI, DCE at
3.0 T
RP Local recurrence None 26 38.5% NA NA
Petronis et al. (1998) [108] SPECT 111In-capromab
pendetide (Prostascint)
Mixed 48 RP, 2 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up 27 33.3% NA NA
Raj et al. (2002) [107] SPECT 111In-capromab
pendetide (Prostascint)
RP Local, lymph nodes,
bone, and soft tissues
Histology in a minority of
patients
202 72.8% NA NA
Sodee et al. (1996) [109] SPECT 111In-capromab
pendetide (Prostascint)
RP Local, lymph nodes,
bone, and soft tissues
None 7 85.7% NA NA
Reinfelder et al. (2017) [133] SPECT-CT 99mTc PSMA Mixed RP, RT, or ADT Local, lymph nodes,
bone, and soft tissues
None 25 40.0% NA NA
Oyama et al. (2003) [63] PET-CT 18F FDG Mixed 30 RP, 16 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
21 0.0% NA NA
Richter et al. (2010) [64] PET-CT 18F FDG Mixed 49 RP, 24 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
28 14.3% 18.2% /
de Jong et al. (2003) [68] PET-CT 11C choline Mixed 20 RP, 16 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
18 0.0% NA NA
Castellucci et al. (2009) [70] PET-CT 11C choline RP Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up 90 22.2% NA NA
Richter et al. (2010) [64] PET-CT 11C choline Mixed 49 RP, 24 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up 28 25.0% 26.9% /
Souvatzoglou et al. (2011) [85] PET-CT 11C choline RP Local or lymph nodes Clinical and imaging follow-up 35 25.7% NA NA
Rybalov et al. (2013) [84] PET-CT 11C choline Mixed 61 RP, 124 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
40 27.5% NA NA
Castellucci et al. (2014) [72] PET-CT 11C choline RP Local, lymph nodes,
bone, and soft tissues
TRUS biopsy, surgical
lymphadenectomy, other
imaging or FU >12 mo
605 28.4% NA NA
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Table 4 (Continued )
Author and year Imaging
type
Tracer Primary therapy Aim detection Standard of reference N Positivity rate Sensitivity Specificity
Giovacchini et al. (2010) [75] PET-CT 11C choline RP Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
226 29.2% NA NA
Krause et al. (2008) [78] PET-CT 11C choline Mixed 42 RP, 21 RT and other Local or lymph nodes Clinical and imaging follow-up,
histology
29 37.9% NA NA
Bertagna et al. (2011) [69] PET-CT 11C choline Mixed 114 RP, 26 RP + RT, 70 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
NA 43.0% NA NA
Mitchell et al. (2013) [80] PET-CT 11C choline Mixed 127 RP, 41 RT, 8 other Local, lymph nodes,
bone, and soft tissues
Histology in a minority of
patients (n = 73), clinical and
imaging follow-up (n = 103)
65 55.4% NA NA
Rinnab et al. (2007) [82] PET-CT 11C choline Mixed 40 RP, 3 RT, 7 BT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
22 72.7% NA NA
Rinnab et al. (2008) [22] PET-CT 11C choline RP  RT and/or HT Lymph nodes Lymph node dissection in all
patients
9 100.0% 100.0% 0.0%
Wieder et al. (2017) [86] PET-CT 11C choline RP Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
15 1/15 local rec,
10/120 LN,
9/120 bone
33.3% local,
58.8% LN, 77.8%
bone
100% local,
100% LN,
98.2% bone
Eiber et al. (2017) [73] PET-CT 11C choline Mixed 57 RP, 13 RT, 5 HT Local, lymph nodes,
bone, and soft tissues
Histology in a minority of
patients (n = 19)
18 61.1–72.2%
local rec,
72.2% LN,
82.4–88.2%
bone
NA NA
Kitajima et al. (2014) [21] PET-CT 11C choline RP Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up 37 NA 45.0% local,
88.9% distant
NA
Scattoni et al. (2007) [23] PET-CT 11C choline RP Lymph nodes Lymph node dissection in all
patients
NA NA 64.0% 85.0%
Johnson et al. (2016) [32] PET-CT 18F choline RT EBRT Local, lymph nodes,
bone, soft tissues
Clinical and imaging follow-up,
histology
4 0.0% NA NA
Cimitan et al. (2015) [90] PET-CT 18F choline Mixed 353 RP, 167 RP + RT, 152
RT, 121 ADT, 207 other
Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
364 36.3% NA NA
Schillaci (2012) [99] PET-CT 18F choline RP Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
19 36.8% NA NA
Chiaravalloti et al. (2016) [89] PET-CT 18F choline RP Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
79 55.7% NA NA
Osmonov et al. (2014) [42] PET-CT 18F choline Mixed 10 RT, 39 RP, 
adjuvant treatment
Lymph nodes Lymph node dissection in all
patients
22 77.3% 80.0% 23.5%
Kwee et al. (2012) [94] PET-CT 18F fluoro(methyl)
choline
Mixed 28 RP, 13 RT, 9 BT Local, lymph nodes,
bone, soft tissues
Clinical and imaging follow-up 19 15.8% NA NA
Cimitan et al. (2006) [48] PET-CT 18F fluoro(methyl)
choline
Mixed 85 RP, 21 RT, 21 ADT Local, lymph nodes,
bone, soft tissues
Clinical and imaging follow-up 40 17.5% NA NA
Morigi et al. (2015) [96] PET-CT 18F fluoro(methyl)
choline
Mixed 22 RP, 4 RT,22 RP + RT Local, lymph nodes,
bone, soft tissues
Histology in a minority of
patients (n = 9)
30 23.3% NA NA
Gauvin et al. (2017) [92] PET-CT 18F fluoro(methyl)
choline
Mixed 33 RP, 26 RT, 1 HIFU Local, lymph nodes,
bone, soft tissues
Clinical and imaging follow-up,
histology
12 25.0% NA NA
Rodado-Marina et al. (2015) [98] PET-CT 18F fluoro(methyl)
choline
Mixed 130 RP, 103 other Local, lymph nodes,
bone, soft tissues
Clinical and imaging follow-up 89 32.6% NA NA
Marzola et al. (2013) [95] PET-CT 18F fluoro(methyl)
choline
RP RP with or without
adjuvant treatment
Local, lymph nodes,
bone, soft tissues
Clinical and imaging follow-up,
histology
144 38.2% NA NA
Vadi et al. (2017) [26] PET-CT 18F fluoro(methyl)
choline
RP Local, lymph nodes,
bone, soft tissues
TRUS or CT biopsy 9 44.4% NA NA
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Tracer Primary therapy Aim detection Standard of reference N Positivity rate Sensitivity Specificity
Esch et al. (2017) [102] PET-CT 11C acetate Mixed 97 RP, 6 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
56 28.6% NA NA
Oyama et al. (2003) [63] PET-CT 11C acetate Mixed 30 RP, 16 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
21 33.3% NA NA
Sandblom et al. (2006) [103] PET-CT 11C acetate RP Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
9 44.4% NA NA
Kotzerke et al. (2002) [37] PET-CT 11C acetate RP Local, lymph nodes,
bone, and soft tissues
TRUS biopsy, clinical and
imaging follow-up
8 62.5% 80.0% 66.7%
Almeida et al. (2017) [100] PET-CT 11C acetate Mixed 213 RP, 251 RT,
229 RP + RT, 38 other
Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology in a minority of
patients (n = 105)
309 81.2% NA NA
Sanli et al. (2017) [120] PET-CT 68Ga PSMA-11 RP Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up 16 31.3% NA NA
Derlin et al. (2018) [125] PET-CT 68Ga PSMA-11 RP  RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
60 31.7% NA NA
Lengana et al. (2018) [117] PET-CT 68Ga PSMA-11 Mixed 28 RP, 21
RP + RT, 12 RT
Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up 23 39.1% NA NA
Sachpekidis et al. (2016) [119] PET-CT 68Ga PSMA-11 RP  RT Local, lymph nodes,
bone, and soft tissues
None 15 46.7% NA NA
Berliner et al. (2017) [127] PET-CT 68Ga PSMA-11 RP Local, lymph nodes,
bone, and soft tissues
Histology in a minority of
patients (n = 2)
54 55.6% NA NA
Ceci et al. (2015) [114] PET-CT 68Ga PSMA-11 Mixed 62 RP ( adjuvant
treatment), 8 EBRT
Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology
37 56.7% NA NA
Verburg et al. (2016) [121] PET-CT 68Ga PSMA-11 Mixed 99 RP  RT,
45 RT, 29 other
Local, lymph nodes,
bone, and soft tissues
Histology in a minority of
patients (n = 18), follow-up in a
minority of patients (n = 7)
46 58.7% NA NA
Schmuck et al. (2017) [126] PET-CT 68Ga PSMA-11 Mixed 209 RP, 31 RT Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up,
histology in a minority of
patients (n = 112)
120 59.2% NA NA
Morigi et al. (2015) [96] PET-CT 68Ga PSMA-11 Mixed 22 RP, 4 RT, 22 RP + RT Local, lymph nodes,
bone, and soft tissues
Histology in a minority of
patients (n = 9)
30 60.0% NA NA
Afshar-Oromieh et al. (2015) [111] PET-CT 68Ga PSMA-11 Mixed 226 RP  RT, 177 RT Local, lymph nodes,
bone, and soft tissues
Histology in a minority of
patients (n = 42)
90 61.1% NA NA
Afshar-Oromieh et al. (2017) [112] PET-CT 68Ga PSMA-11 Mixed 828 RP, 600 RT Local, lymph nodes,
bone, and soft tissues
None 462 65.2% NA NA
Eiber et al. (2015) [116] PET-CT 68Ga PSMA-11 RP Local, lymph nodes,
bone, and soft tissues
None 124 82.3% NA NA
Meredith et al. (2016) [34] PET-CT 68Ga PSMA-11 Mixed 425 RP, 107 RT Local, lymph nodes,
bone, and soft tissues
None 316 total,
291 RP,
25 RT
35.7% total,
31.9% RP,
80.0% RT
NA NA
Gupta et al. (2017) [33] PET-CT 68Ga PSMA-11 Mixed 75 RP, 70 RT Local, lymph nodes,
bone, and soft tissues
None 54 (49 RP,
5 RT)
40.7% total
(40.8% RP,
40.0% RT)
NA NA
Odewole et al. (2016) [49] PET-CT 18F FACBC
(fluciclovine)
Mixed 7 RP, 5 RT, 41 other Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up
5 yr
17 58.8% NA NA
Mena et al. (2018) [129] PET-CT 18F DCFBC Mixed 50 RP, 9 RT, 9 RP + RT Local, lymph nodes,
bone, and soft tissues
Histology in a minority of
patients (n = 18)
38 47.4% NA NA
Hope et al. (2017) [123] PET-CT or
PET-MRI
68Ga PSMA-11 Mixed 43 RP, 41 RT, 9 other Local, lymph nodes,
bone, and soft tissues
Clinical and imaging follow-up 60 68.3% NA NA
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E U RO P E AN URO L OGY ONCO L OGY 2 ( 2 019 ) 47 – 7662example, only able to evaluate local recurrence because of
their limited coverage of the treated prostate and pelvic
lymph nodes. This necessitates the use of other comple-
mentary imaging modalities to detect or exclude distant
metastatic disease in order to obtain a comprehensive
diagnostic workup. On the contrary, BS exclusively detects
osteoblastic bone metastases, but provides no information
on the presence of metastatic lymph nodes or local
recurrence (Supplementary Table 4). For lymph node
detection (Supplementary Table 5) or evaluation of visceral
metastases, morphological CT or MRI is traditionally used
[20–23].Whole-bodyMRI, PET-CT, or PET-MRI allowall sites
to be evaluated at the same time, enabling a comprehensive
evaluation of the patientwith BCR [24]. Theymay play a role
as single-step diagnostic procedures in the detection of
lymph node or bone metastases, and may also highlight
local relapse. Some imaging techniques such as MRI may be
deliberately limited to the axial skeleton or spine but ignore
the skull, ribs, and limbs. The probability of finding
metastases in the latter locations with no metastases in
the axial skeleton is however negligible, especially in PCa,
which predominantly metastasizes to the spine and pelvis
[25]. In our systematic review, unfortunately few of the
studies about these all-in-one imaging modalities specify
separately the performance characteristics and proportion
of purely local recurrences versus distant metastases and
their different sites.
Currently, mpMRI is most frequently used to assess local
relapse and is combined with whole-body (PET)-CT to find
regional or distant relapse; it also has an incremental value
in facilitating the detection of local recurrence
[21,26,27]. An alternative approach has been described,
consisting in an “MRI-only” approach combiningmpMRI for
local relapse and wbMRI for bone and node screening
[28,29].
3.3.2. Primary treatment
In most studies of this systematic review, primary
treatment of patients developing BCR was very heteroge-
neous. Papers mixing patients with histories of primary RP
and RT are difficult to interpret and compare. Preferably,
studies should have entire cohorts with the same primary
treatment and similar treatment histories, to better
investigate the performance of a given imaging technique
under a variety of predefined conditions. This was, for
example, the case in the studies of Chondrogiannis et al.
[30], Einspieler et al. [31], and Johnson et al. [32], who only
included patients treated with primary RT. Alternatively,
the imaging performance results of a heterogeneous study
population could be reported separately depending on the
type of treatment, but this was not the case in most studies,
except for the papers of Gupta et al. [33] and Meredith et al.
[34], where the imaging performance between patients
previously treated with RP as compared with primary RT
were separately reported.
3.3.3. Standard of reference
Histopathology as the gold standard was available in only a
minority of studies (Supplementary Table 6). In only seven
Table 5 – Summary of the roles of imaging modalities in the setting of early recurrent prostate cancer
Imaging modality Number
of studies
Percent related to total
studies of 98
Imaging directed to Role of imaging modality in the early recurrence setting
TRUS 5 5.1% Local only Readily available useful adjunct to PSA and DRE after RP, and
has reasonable positivity at low PSA levels; after RT there are
no studies in the early recurrence setting
CT 3 3.1% Lymph nodes
and bone
Traditionally used to restage patients with biochemical
recurrence, but not sufficiently sensitive to localize
recurrence at low PSA values
BS 3 3.1% Bone only Frequently used because of low cost and wide availability,
but low sensitivity in the early recurrence setting and
hampered by a high number of equivocal findings
SPECT
111In-capromab
pendetide (Prostascint)
4 4.1% All in one All studies published >10 yr ago; may have been useful in
detecting the site of recurrence when conventional imaging
is negative
99mTc PSMA 2 2.0% All in one Limited evidence; may detect more metastatic lesions and
achieve higher detection rates than conventional imaging
PET-CT 93 80 (81.6%)
18F FDG 4 4.1% All in one Limited value in prostate cancer due to low glucose
metabolism in most prostate cancer cells and disturbing
tracer accumulation in the bladder hampering local
recurrence detection
11C choline 26 26.5% All in one Widely available useful diagnostic tool in biochemical
recurrence and also in the early setting
11C acetate 10 10.2% All in one Performs in a similar manner to 11C choline but is not as
extensively used; higher detection rate for local recurrent
PCa
18F (fluoro)choline 23 23.4% All in one Alternative tracer for 11C choline, with advantages of 18F
labeling
18F FACBC (fluciclovine) 3 3.1% All in one Relatively new tracer with sensitivity appearing to be higher
than 11C choline
68Ga PSMA-11 21 21.4% All in one Higher detection rates than any other imaging modality,
especially in the range of low PSA values (<0.5 ng/ml)
18F DCFPyL 1 1.0% All in one Noninferior to 68Ga PSMA-11 while offering the advantages
of 18F-labeling
18F DCFBC 1 1.0% All in one 18F labeled PSMA-targeted tracer but limited evidence in the
early recurrence setting
PET-MRI 5 5.1% All in one Allows for improved anatomic correlation of PET tracer
uptake in intraprostatic recurrence or in bone marrow
metastasis, but longer scanning time and not as widely
available as PET-CT
mpMRI 10 10.2% Local only Excellent technique for local recurrence, superior than PET-
CT, even at low PSA, but provides no information about
extrapelvic lymph nodes or bone metastases
wbMRI 4 4.1% Lymph nodes and bone Higher sensitivity than BS for the detection of bone
metastases; dedicated scan sequences (such as diffusion-
weighted imaging) allow for high detection rates of
pathological lymph nodes
Total 124 98 (100%)
BS = bone scintigraphy; CT = computed tomography; DRE = digital rectal examination; FDG = fluoro-deoxy-glucose; FU = follow-up; HIFU = high-intensity
focused ultrasound; mpMRI = multiparametric MRI; MRI = magnetic resonance imaging; PCa = prostate cancer; PET = positron emission tomography;
PSA = prostate-specific antigen; PSMA = prostate-specific membrane antigen; RP = radical prostatectomy; RT = radiotherapy; SPECT = single-photon emission
CT; TRUS = transrectal ultrasonography; wbMRI = whole-body MRI.
E U RO P E AN U RO LOGY ONCO LOGY 2 ( 2 019 ) 47 – 76 63studies (7.1%) [26,35–40] aimed at the detection of local
recurrence, imaging was performed in all patients followed
by systematic TRUS-guided biopsy of the vesicourethral
anastomosis or the irradiated prostate to confirm local
recurrence. In only five studies (5.1%) evaluating pelvic
lymph node metastases, subsequent laparoscopic or open
extended pelvic lymphadenectomy was performed as a
standard of reference in all patients [22,23,41–43]. In
57 studies (58.2%), imaging results were validated by a
surrogate standard of reference, consisting of a heteroge-
neous composite including all the following and performed
at the discretion of the referring clinician: (1) durablefollow-up PSA control achieved after therapy directed to the
scan-positive site deemed as proof of disease in the treated
lesions and absence of disease elsewhere; (2) concordant
findings on other correlative imaging studies or confirma-
tion by subsequent imaging with the same technique; (3)
spontaneous decline of PSA without therapy interpreted as
an overall absence of disease; (4) long-term follow-up, for
example, 2–5 yr; and (5) consensus achieved by a
multidisciplinary board comprising nuclear medicine phy-
sicians, urologists, and radiation oncologists.
In a substantial number of studies, a standard of
reference to validate the imaging results was completely
E U RO P E AN URO L OGY ONCO L OGY 2 ( 2 019 ) 47 – 7664lacking. In 11 studies (11.2%), a biopsy was performed in
only a minority of patients, and in 10 studies (10.2%), there
was no reference standard at all. In studies without
histological confirmation of the imaging findings, only
“positivity” (sometimes referred to as “detection rate”) of
the imaging test was reported.
3.4. Specific findings of the different imaging modalities
3.4.1. Transrectal ultrasound
TRUS is frequently used in patients with BCR as an adjunct
to digital rectal examination (DRE) to detect local recur-
rence. In the literature search of this systematic review, only
a few papers on TRUS met the inclusion criteria for imaging
in the early recurrence setting [35–38,40]. Many papers
report on the performance of TRUS biopsies but do not
specify the imaging findings. Nevertheless, we found five
papers reporting the performance of TRUS in patients after
RP with rising PSA not higher than 2 ng/ml [35–38,40]
(Supplementary Table 7), with two of them even reporting
the performance in a (sub)group of patients with rising PSA
not higher than 0.5 ng/ml [35,40]. They report that after
RP, TRUS can occasionally show local recurrence as a
hypoechoic nodular mass identified in the perianastomotic
area, at the level of the bladder neck or in the retrovesical
space, although any asymmetric thickening or fullness or
obvious distortion of the urethrovesical anastomosis, or loss
of the integrity of the retroanastomotic plane may all be
considered to be suggestive of local recurrence [35,38]. The
reported detection rates at PSA levels 0.5 ng/ml are 28.1%
in the study of Connolly et al. [35] and 73.0% in the study of
Scattoni et al. [40]. At PSA levels not higher than 2 ng/ml, the
reported positivity rates vary from 30.8% to 75.0%,with
sensitivities between 69.0% and 100% and specificities
between 63% and 90%. These numbers suggest that TRUS
has reasonable positivity at very low PSA values. TRUS
seems to be more sensitive but less specific than DRE
[35,36,38]. We did not find any study evaluating TRUS after
primary RT in the early recurrent setting. It has been
reported that after primary RT the prostate appears
diffusely hypoechoic at TRUS and that the detection of
local recurrences is not reliable enough to play a role
because the results are close to those of DRE [44,45]. Color/
power Doppler or contrast-enhanced TRUS or multipara-
metric ultrasound may increase the sensitivity and speci-
ficity of gray-scale TRUS by facilitating the identification of
hypervascular areas within the prostatic fossa, and help
improve the distinction between recurrent cancer and
postoperative fibrosis [44]; however, they have not yet been
assessed in the early recurrence setting.
3.4.2. Computed tomography
The limited role of CT in the detection of local recurrence or
distant metastases in patients with BCR is well known
[20,46]. Kane et al. [47] reported that the probability of a
positive CT scan within 3 yr after initial onset of BCR was
only 14.0%, even in patients with high recurrent PSA values.
In our systematic review, we found three studies reporting
the detection rates of CT in the setting of early PCarecurrence at PSA values<5 ng/ml (Supplementary Table 8)
[48–50]. Seltzer et al. [50] reported a detection rate of only
17% formetastatic lymph nodes in patients with PSA relapse
<4 ng/ml. Odewole et al. [49] reported a whole-body
positivity rate of CT of only 12.5% in patients with PSA
1 ng/ml and 0% in patients with PSA 1–2 ng/ml. Only in six
of 29 (20.7%) patients with PSA 5 ng/ml, CT was positive,
whereas 18F FACBC (fluciclovine) PET-CT in the same group
of patients had a positivity of 72.4% (21/29). Cimitan et al.
[48] reported a CT positivity rate of only 25.0% in patients
with PSA 0.5 ng/ml and 20.0% in patients with rising PSA
levels 1 ng/ml. The low accuracy in the detection of local
recurrence is not surprising because differentiation of a
local recurrence from postsurgical scarring is difficult on CT.
The poor performance in the detection of lymph node
metastases can be explained by the fact that CT relies solely
onmorphological and size criteria to consider a lymph node
suspicious (usually>10 mm short-axis diameter for an oval
lymph node and >8 mm diameter for a round lymph node),
but many normal-sized lymph nodes may still contain
microscopicmetastases. It is thus clear that the technique of
CT is limited for detecting local recurrence or metastatic
disease in patients with low PSA.
3.4.3. Multiparametric MRI
In mpMRI, high-resolution morphological T2-weighted
images (T2-WI) are combined with functional imaging
sequences such as diffusion-weighted imaging (DWI),
dynamic contrast-enhanced MRI (DCE-MRI), and/or mag-
netic resonance spectroscopic imaging. DCE-MRI seems to
be particularly accurate to differentiate PCa recurrence from
postoperative fibrosis and scar tissue. After RP, PCa
recurrence can be recognized as a lobulated soft tissue
mass in the perianastomotic area, slightly hyperintense on
T2-WI andwith contrast enhancement on DCE. After RT, the
prostate shrinks and shows diffuse low signal intensity on
T2-WI, hampering the detection of recurrence. Recurrent
PCa typically has a lower apparent diffusion coefficient
(ADC) on DWI, and shows stronger and earlier contrast
enhancement on DCE than the surrounding irradiated
benign tissue.
Many studies about the role ofmpMRI in the detection or
PCa recurrence have included patients at low PSA values,
but unfortunately, they do not separately report the
numbers of patients and detection rates in the subgroups
with low PSA. We found 10 studies [21,39,51–58] reporting
mpMRI performance in the early recurrence setting, but all
of them were performed in patients primarily treated with
RP (Supplementary Table 9).We found no papers on the role
of mpMRI in the early recurrent setting after RT. Overall, in
patients with BCR after RP with rising PSA levels 5 ng/ml,
positivity rates varied from 66.7% to 86.7% and sensitivity
was around 90%. In lower PSA (sub)groups, mpMRI still
seems to be able to define areas of local recurrence. Counago
et al. [52] reported a positivity rate of 12.9% in patients with
PSA0.5 ng/ml. Linder et al. [39] showed a positivity rate of
94.0%, sensitivity of 86%, specificity of 45%, a positive
predictive value (PPV) of 86.0%, and a negative predictive
value (NPV) of 45.0% in patients with PSA<0.4 ng/ml. Liauw
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PSA 0.2 ng/ml, 17.0% in patients with PSA 0.5 ng/ml, and
19.0% in patients with PSA 1 ng/ml, but the detected
lesions were not confirmed with any standard of reference,
so sensitivity and specificity are not known. Rischke et al.
[56] reported sensitivity of 66.7%, specificity of 100%, a PPV
of 100%, an NPV of 75.0%, and accuracy of 83% for mpMRI
after RP, at PSA levels 2.38 ng/ml. Vees et al. [58] obtained
a positivity rate of 85.0% in a group of patients with BCR
after RP with PSA 1 ng/ml. In a study of Panebianco et al.
[55], in 116 patients with PSA 1.4–2.9 ng/ml, sensitivity of
94–100%, specificity of 92–97%, PPV of 91–96%, and NPV of
89–95% were reported. DCE-MRI was the most reliable
technique in detecting local PCa recurrence, but DWI could
be proposed as a reliable alternative. In another study of the
same authors [54], mpMRI was compared with 18F choline
PET-CT for local recurrence, and showed sensitivity of 92.0%,
specificity of 75.0%, and a positivity rate of 82.1% at PSA
levels of 0.8–1.4 ng/ml. At PSA levels of 1.3–2.5 ng/ml,
sensitivity of 94.0%, specificity of 100.0%, PPV of 96–100%,
and NPV of 57–60% were reported. The diagnostic accuracy
of mpMRI was higher than that of 18F choline PET-CT for the
detection of local recurrence. Similarly, in the study of
Kitajima et al. [21], mpMRI was more accurate than 11C
choline PET-CT for the detection of local recurrence after RP.
This may be explained by the higher spatial resolution of
mpMRI and by the fact that in mpMRI there is no
confounding tracer accumulation in the urinary bladder,
which is a disadvantage of 11C choline PET imaging. Anyhow,
with mpMRI being superior for local recurrence and PET-CT
being superior for pelvic LN or bone metastases, they are
complementary for restaging patients with recurrent PCa.
3.4.4. Bone scan
For the detection of bone metastases in patients with PCa,
99mtechnetium-methylene diphosphonate BS (“bone scan”)
is the traditional and established imaging modality, thanks
to its widespread availability and affordability. BS can
readily detect widespread polymetastatic disease in
patients with high PSA levels, but the diagnostic yield is
much lower in the early recurrence setting. In 1998, Cher
et al. [59] already reported that the probability of positive BS
was<1%when the PSA rise after RP is<10 ng/ml. Kane et al.
[47] reported a probability of positive BS of only 4.5% in
patients with BCR with PSA level <10 ng/ml. In our
systematic review, we found three studies reporting
detection rates of BS in the early recurrence setting
(Supplementary Table 10) [48,60,61]. Picchio et al. [60]
reported a detection rate of 19% at PSA levels <1.4 ng/ml
with neither false positives or false negatives, and Su et al.
[61] reported that BS identified metastatic bone lesions in
10.0% of patients with PSA1.0 ng/ml and in 20% of patients
with PSA 1–4 ng/ml. These rather low detection rates as
compared with other newer imaging modalities such as
wbMRI and PET-CT indicate that BS seems to systematically
underestimate the burden of bonemetastases. The problem
is that BS depicts only secondary reparative effects, which
results in a time lag between marrow involvement and BS
positivity. Moreover, BS is hampered by a large number ofinconclusive results because it is difficult to distinguish
betweenmetastases and other pathological conditions such
as degenerative joint disease, inflammatory changes, or
recent trauma. This warrants additional targeted morpho-
logical imaging with radiography, CT, or MRI in about 16% of
the cases [60]. BS also has the disadvantage that it assesses
only the skeleton, warranting the use of other imaging
techniques to evaluate local or nodal relapse. Owing to all
these aforementioned shortcomings, in routine clinical
practice BS is usually omitted in patients with early BCR.
3.4.5. PET-CT
A hybrid PET-CT examination offers a combination of
metabolic information provided by PET imaging, and
detailed anatomic localization and morphological correla-
tion provided by CT imaging. PET-CT has overcome many
limitations of conventional imaging, resulting in more
accurate assessment of patients with BCR. PET-CT detects,
for example, affected lymph nodes that are not patholog-
ically enlarged on CT. Since the turn of the century, many
new radiopharmaceutical agents showing a tropism for PCa
cells have been introduced, such as 11C choline, 11C acetate,
18F choline, 18F FACBC (fluciclovine), and 68Ga PSMA-based
tracers. With the rising number of PET centers, these are
increasingly available and used in clinical practice world-
wide, especially in the recurrence setting.
3.4.5.1. 18F FDG PET-CT. The 18F FDG-PET imaging modality is
the mainstay of molecular imaging and has demonstrated
clinical usefulness in many tumors such as lung cancer,
colorectal cancer, and melanoma, but has been proved to be
of limited value in PCa due to low glucose metabolism in
most PCa cells and because renal excretion with tracer
accumulation in the bladder disturbs the evaluation of
lesions in the prostate [60,62]. In high-grade and castration-
refractory PCa, glucose metabolism is higher and 18F FDG
PET-CT may work better. In our systematic review, four
studies were found (Supplementary Table 11) [50,63–65] to
evaluate the role of 18F FDG PET-CT in the early PCa
recurrence setting, but the detection rates for patients with
PSA relapse of <5 ng/ml were very low, ranging from 4% to
15% [50,63,64]. In the study of Oyama et al. [63], 18F FDG
PET-CT was not even able to detect any lesion at PSA levels
<2 ng/ml. Richter et al. [64] reported a detection rate of 13%
for PSA <1 ng/ml and 14% for PSA <2 ng/ml, corresponding
to sensitivities of 15% and 18%, respectively. Schoder et al.
[65] showed that a threshold PSA level of 2.4 ng/ml and a
PSA velocity of 1.3 ng/ml/yr provided the best tradeoff
between sensitivity (80%; 71%) and specificity (73%; 77%)
for 18F FDG PET-CT.
3.4.5.2. 11C choline PET-CT. Choline is a component of the
phospholipids in cell membranes, and the PET tracer 11C
choline can be used to detect tissues such as PCa that show
increased cell proliferation with upregulation of choline
kinase and choline transporters and increased expression of
choline transporters [66]. Detection rates of 11C choline PET-
CT mainly depend on the site of recurrence and the PSA at
the time of imaging. Detection of local recurrence with 11C
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choline in the prostatic bed and bladder-urethral junction is
difficult to differentiate from radioactive urine accumula-
tion. The performance of 11C choline PET-CT for the
detection of local recurrence seems to be inferior to that
of mpMRI [67], but 11C choline PET-CT is better than CT or
MRI for lymph node metastases. Both wbMRI and 11C
choline PET-CT are excellent for the detection of bone
metastases and superior to BS because early bone marrow
infiltration may be detected before osteoblastic reaction
occurs.
Studies on 11C choline PET-CT are abundant, and we
found 25 studies reporting detection rates in the early
recurrent setting [21–23,41,43,60,64,68–86]. In one study,
11C choline PET-MRI was compared head-to-head with 11C
choline PET-CT [73]. At PSA levels below 1 ng/ml, 12 studies
reported the performance of 11C choline PET-CT in a (sub)
group of>10 patients [43,64,68,70,72,75,76,78,80,81,84,85]
(Supplementary Table 12), with positivity rates ranging
from 14.3% to 44.1%. Only Gomez-de la Fuente et al. [76] also
reported the sensitivity and specificity at these PSA levels to
be 77.8% and 65.9%, respectively. The 11C choline PET-CT at
PSA levels below 0.5 ng/ml was reported in subgroups
of > 10 patients in five studies [68,75,79,80,85], with
positivity rates ranging between 0% and 31.3%, but none
of these studies reported sensitivity or specificity. The low
detection rates at PSA levels below 1 ng/ml may partially be
explained by slow proliferation of PCa cells and slow
membrane metabolism resulting in only a small amount of
11C choline uptake. Another problem is that choline is not
cancer specific and also shows potential uptake in areas of
benign inflammation such as in reactive lymph nodes or in
degenerative bone disease introducing false positive results.
False negative results may occur in micrometastatic (tumor
deposit of <2 mm) adenopathies. Unexpected metastatic
deposits may be detected in lymph nodes outside the pelvis
or bone in 13–21% of patients referred for evaluation of local
recurrence with 11C choline PET-CT [71,85]. Imaging tech-
niques 11C choline PET-CT and mpMRI are complementary
for restaging in suspected recurrent disease, and both can
be recommended for evaluation in early biochemical
relapse.
3.4.5.3. 18F (fluoro)choline PET-CT. Tracers such as 18F (fluoro)
choline are a group of PET tracers that may be used as
alternative tracers in PCa (Supplementary Table 13)
[18,19,26,30,32,41,42,48,54,58,87–99]. The most remark-
able differences between 18F choline and 11C choline are
the following: half-life is 110 min for 18F choline and 20 min
for 11C choline, and urinary excretion of 18F choline is higher
than that of 11C choline. The latter hampers the detection of
local recurrence, and this was demonstrated by Panebianco
et al. [54]who showed higher diagnostic accuracy ofmpMRI
than 18F choline PET-CT to identify local PCa recurrence. In
patients with BCR and PSA <0.5 ng/ml, detection rates of
8.3–28.1% using 18F fluorocholine PET-CT are reported
[48,94–96]. In patients with BCR and PSA <1 ng/ml,
detection rates are higher, ranging from 16.7% to 76.0%
[42,48,58,88–91,95,97–99]. For the staging of bone metas-tasis, 18F choline and 18F fluoride PET-CT appear to perform
better than BS because they may detect early bone marrow
infiltration before osteoblastic reaction occurs. Schillaci
et al. [99] additionally suggested that for staging of bone
metastases with 18F choline PET-CT, the use of an
intravenous contrast agent may be unnecessary. For the
detection of lymph nodemetastases, the performance of 18F
choline PET-CT seems to be limited due to a high false
positive rate [42].
3.4.5.4. 11C acetate PET-CT. The PET tracer 11C acetate can detect
increased lipidmetabolism in PCa and their metastases [66]
such as 11C choline. However, in clinical practice, 11C acetate
is not as extensively used [62] (Supplementary Table 14)
[18,19,37,51,58,63,100–103]. The tracers 11C acetate and 11C
choline perform in a similar manner. Lamanna et al. [18]
compared PET-CT and PET-MRI with 11C acetate and 18F
fluorocholine, and found minor discrepancies. They
reported true positivity in half of cases and treatment
change influenced by PET in a third of cases. Buchegger et al.
[19] reported excellent concordance in an intra-individual
comparison of 11C acetate and18F fluorocholine, on both per-
lesion and per-patient analysis. At PSA levels <1 ng/ml,
detection rates of 28.6–73.9% are reported
[51,58,63,100,102]. Oyama et al. [63] reported that 11C
acetate PET-CT showed more frequent uptake in the
prostate bed and lymph nodes than 18F fluorocholine
PET-CT. In the early recurrence setting, only a minority of
patients with BCR appear to benefit from 11C acetate PET-CT
[102]. For local recurrence after RP, in the study of Vees et al.
[58], 11C acetate PET-CT detected local relapse in about half
of patients with BCR <1 ng/ml. False positive results occur,
which show that factors other than tumor metabolism may
induce increased uptake [102,103].
3.4.5.5. 18F FACBC (fluciclovine) PET-CT. The radiotracer 18F FACBC
(Fluciclovine) is a relatively new synthetic amino acid–
based PET radiotracer that is approved by the Food andDrug
Administration and EuropeanMedicines Agency [49]. Three
papers, all published in 2016, report on its role in the setting
of early recurrent PCa [49,81,104] (Supplementary Table 15).
In patients with BCR and PSA <1 ng/ml, detection rates of
21.4–41.4% are reported [49,81,104]. Bach-Gansmo et al.
[104] report that 18F FACBC (fluciclovine) PET-CT detects
extraprostatic involvement in approximately 30% of
patients in the PSA quartile of 0.79 ng/ml. Nanni et al.
[81] compared, in a prospective study, the performance of
18F FACBC (fluciclovine) PET-CT with 11C choline PET-CT and
demonstrated statistically superior sensitivity of 18F FACBC
(fluciclovine) PET-CT, particularly significant in the lowest
PSA subgroup (<1 ng/ml; 21% vs 14%). Detection rates of 18F
FACBC (fluciclovine) PET-CT were higher than those of 11C
choline PET-CT overall, for local, lymph nodal, and bone
relapse. The 18F FACBC (fluciclovine) PET-CT imaging also
showed higher sensitivity (37% vs 32%) and specificity (67%
vs 40%) than 11C choline PET-CT [81].
3.4.5.6. PET-CT with PSMA-based tracers. The most promising
data to date have been generated with radiotracers
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cells [105]. The imaging agent 111In-capromab pendetide
(Prostascint) was the first to target PSMA, but the scans
were limited by SPECT imaging. They were technically
challenging to read and expensive to perform because 111In-
capromab pendetide (Prostascint) is a large tracer targeting
the intracellular domain of PSMA, with long half-life and
long blood-pool activity resulting in inferior image quality.
We found four papers on this imaging technique, published
between 1996 and 2002, reporting detection rates in BCR
with PSA levels<1 ng/ml ranging from 60.0% to 79.0% [106–
109] (Supplementary Table 16).
Since 2012, 68Ga PSMA HBED-CC or 68Ga PSMA-11 PET-
CT has been introduced, which is a tracer targeting the
extracellular domain of PSMA. The imaging technique 68Ga
PSMA-11 PET-CTappears to be superior to PET-CTwith older
tracers predominantly owing to increased avidity of uptake
and a favorable lesion-to-background ratio of 68Ga PSMA-11
[110]. In patients with recurrent PCa, higher detection rates
than any other imaging modality are observed, especially
for smaller lesions at low PSA values (Supplementary
Table 17) [31,33,34,96,111–124]. In the study of Gupta et al.
[33], in patients with nil or three or fewer lesions on
conventional imaging, 68Ga PSMA-11 PET-CT detected at
least one lesion in 80% of all scans. In our systematic review,
eight papers [33,34,111,112,119,123,125,126] report the
detection rates of 68Ga PSMA-11 PET-CT at PSA levels
<0.2 ng/ml. The detection rates ranged from11.3% to as high
as 58.3%. In patients with PSA <0.5 ng/ml, detection rates
ranged from 11.0% to 65.0% [33,34,96,111–113,115–120,122–
127]. In a study of Afshar-Oromieh et al. [111], lesion-based
sensitivity of 76.6%, specificity of 100%, NPV of 91.4%, and
PPV of 100% were reported. Thus, 68Ga PSMA-11 PET-CT has
very high specificity but moderate sensitivity for lymph
node metastasis detection, which may imply some under-
estimation of disease load (although less pronounced than
with other PET tracers). Other disadvantages of 68Ga PSMA-
11 are urinary excretion and some tumors that appear to
have no or only very low expression of PSMA [128]. Despite
these limitations, 68Ga PSMA-11 PET-CTappears to allow for
more complete and accurate restaging of PCa patients
compared with standard routine imaging. Nowadays, 68Ga
PSMA-11 PET-CT is increasingly being performed world-
wide, but in many countries it is not available.
Many more new PSMA-based tracers are now arising,
such as 18F-PSMA-1007, 18F-DCFBC, 99mTc PSMA, etc.
[61,62,129–133]. The future of PSMA-based PET imaging
will probably be with 18F-labelled tracers because of the
practical advances; 18F namely has a long half-life, which
enables the tracers to be distributed to PET centers without
a cyclotron and to be easily handled in clinical routine.
3.4.5.7. Other PET tracers. Other emerging innovative PET
radiotracers for PCa have been proposed, such as 18F-
bombesin, 18F-fluoro-5a-dihydrotestosterone, and uroki-
nase-type plasminogen activator receptor, but these are not
widely used in clinical practice and few scientific data were
available at the time of our literature search, especiallyabout their use in the early recurrence setting of PCa
[62,129–131].
3.4.6. Whole-body MRI
Owing to recent technical improvements of MRI scanners
and development of sequences with faster temporal
resolution, it has become possible to scan the whole body
with MRI within a reasonable time frame to detect
metastases in the bone and extraskeletal anatomic loca-
tions, including lymph nodes (Supplementary Table 18)
[26,61,86,134]. A faster dedicated MRI bone scanning
protocol limited to the whole spine and pelvis with
conventional sequences (T1, T2) may be applied, but it
ignores costal metastases, (rare) long bone metastases, and
lymph node metastases; nevertheless, this approach out-
performs BS for bone metastasis detection [25].
For the detection of bone metastases, MRI has higher
sensitivity than any imaging technique focusing on cortical
destruction or reactive/repair processes such as BS because
due to high spatial resolution and high contrast between fat
and metastases in the hematopoietic bone marrow,
metastases can be identified on MRI before osteoblastic
reaction occurs [135].
For lymph node assessment, anatomical MRI performs
poorly, equally to CT, because both of them use only
morphological and size criteria to consider a lymph node
suspicious, as mentioned before [20]. In the past, MR
lymphography, a technique that used intravenously injected
ultra-small particles of iron oxide, showed promising
results for the detection of lymph metastases in PCa
patients, but these agents are not commercially available
at present [136]. Diffusion-weighted MRI may help charac-
terize lymph nodes since highly cellular metastatic lymph
nodes show decreased water diffusion, resulting in lower
ADC values than healthy lymph nodes. Preliminary results
of DWI in this setting were promising; however, a
substantial overlap between ADC values of benign and
malignant lymph nodes has been documented.Wieder et al.
[86] compared 11C choline PET-CT with DWI-wbMRI, and
showed that 11C choline PET-CT was superior in the
detection of local recurrence and bone metastases on a
regional basis and wbMRI showed similar accuracy only for
the detection of lymph nodes and could therefore not serve
as a one-stop alternative imaging modality to PET-CT for
restaging PCa. Moreover, before wbMRI will find its way to
application in routine practice, some issues, such as
reproducibility and economical impact, have to be resolved
because one of the disadvantages of wbMRI is the enormous
increase in image data, which implies an increase in
evaluation time for the radiologist. Comparisons of accep-
tance, costs, acquisition, and reading times of wbMRI and
PET/CT, however, show that wbMRI is regarded by the
patients at least as acceptable as abdominopelvic CT or
nuclear medicine examinations, takes about the same time
for reading, is less expensive, and does not expose patients
to radiation [137]. Whole-body studies combining mpMRI
and whole-body sequences have been used in 76 patients
with BCR, some with very low PSA levels (median 0.36 ng/
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the prostatic bed, lymph nodes, and bones [29].
3.4.7. PET-MRI
PET-MRI combines the functional and molecular informa-
tion of PET with morphological information of MRI. The
advantages of PET-MRI over PET-CT include better anatom-
ical correlation of tracer uptake in the intraprostatic lesion
and in bonemarrow, both of which are not feasible when CT
is used. Drawbacks of PET-MRI are limited availability and
substantially longer scan time of about 1 h. Only very few
studies on PET-MRI have been published in the PCa
recurrence setting, mainly using 11C choline or 68Ga
PSMA-11 as tracers (Supplementary Table 19) [18,73,122–
124]. Eiber et al. [73] showed in a prospective head-to-head
comparison of 11C choline PET-MRI with 11C choline PET-CT
that PET-MRI had a higher detection rate of local recurrence
than PET-CT, most advantageous in patients with PSA
<2 ng/ml. In patients with PSA >2 ng/ml, PET-CT however
performed slightly better than PET-MRI in the detection of
bone and lymph node metastases. Kranzbuhler et al. [124]
showed that 68Ga PSMA-11 PET-MRI is a promising
potential tool for restaging PCa patients with early BCR at
low PSA values. MRI in PET-MRI is usually limited to only a
high-resolution T2-weighted sequence in one plane, but
PET-MRI may also be supplemented with pelvic mpMRI in
the same session, which combines the excellent capability
of 68Ga PSMA-11 PET for the detection of distant metastases
with the high spatial resolution and functional DCE andDWI
information of mpMRI necessary for the detection of local
recurrence [27].
3.5. Diagnostic yield and PSA
The influence of the level of PSA at the time of imaging on
the diagnosis of PCa relapse is a constant in all studies,
independently of the imaging modality used. The perfor-
mance in BCR appears to be crucially better when PSA
values are higher, with an almost linear relationship. The
lower the PSA value, the less likely that a scan result will be
positive.
This does not necessarily mean worse performance of
the imaging technique itself, but may rather indicate lower
volume and number of metastases or a smaller size of local
recurrence. It may after all just be impossible to demon-
strate microscopic disease with “macroscopic” imaging.
Nevertheless, even patients with PSA <0.2 ng/ml may
already have visible recurrent metastatic disease. In the
current standards, patients are referred for salvage RT after
RP when PSA values are preferably still below 0.5 ng/ml,
owing to the decrease in biochemical control that could
occur when delaying treatment until the levels of PSA are
higher [4,8,52].
In the studies included in this systematic review,
selection of patients and PSA levels at the time of imaging
varied largely. In some studies, only patients with BCR and
PSA<1 ng/ml were included; in other studies, patients with
any recurrent PSA value were present, but the performance
of the imaging technique was divided in subgroups. Thesesubgroups were in some studies “all patients with BCR and
PSA <5 ng/ml” and in other studies “all patients with PSA
between 2 and 5 ng/ml,” but the difference between these
groups is essential because the latter excludes all patients
with PSA below 2 ng/ml. This results in a wide range of
reported detection rates, sensitivities, and specificities with
much variability between papers. Therefore, to enable a
comparison between the different papers, we stratified the
imaging performance results according to predefined PSA
groups and merged or calculated the detection rates from
the reported patient (sub)groups.
An optimal PSA threshold that would justify imaging
would be interesting, because imaging cannot be recom-
mended in all patients. The threshold should be based on
the likelihood of positivity for each imaging technique and,
more importantly, based on the implications of the imaging
findings on clinical management. Counago et al. [52]
reported an optimal PSA threshold of 0.5 ng/ml for positive
mpMRI for the detection of local recurrence. Optimal PSA
thresholds for PET-CT were suggested in many studies but
varied depending on the radiotracer used. For 18F fluor-
ocholine 2.6 ng/ml [92] and 4 ng/ml were proposed
[48]. Lower PSA thresholds were suggested for 11C acetate,
namely,1.09 ng/ml by Almeida et al. [100] and 1.24 ng/ml by
Dusing et al. [101], resulting in positivity likelihoods of
76.2–80.0%. For 11C choline, the proposed optimal PSA
thresholds varied from 1.05 to 2.43 ng/ml, resulting in
sensitivities of 73–89%, specificities of 69–92.5%, and
positivity rates of up to 73% [69,70,72,75,77,78,80,83]. For
PSMA-targeting tracers, Sanli et al. [120] reported an
optimal PSA threshold of 0.67 ng/ml and Hope et al. [123]
suggested 1.5 ng/ml, but other authors suggested values as
high as 2 ng/ml [33,34,116,117,122,127], resulting in the
likelihood of a positive scan of 80–100%. Rauscher et al.
[118] present a nomogram to assess the a priori probability
of 68Ga PSMA-11 PET-CT scan positivity, based on clinical
variables. It is a first step toward better patient selection and
to potentially help spare resources for those subgroups in
which positive PET-CT might tailor salvage procedures or
medical treatment and potentially influence outcome.
Several authors have demonstrated that not only the
absolute PSA value at the time of the imaging, but also PSA
kinetics such as PSA velocity and PSAdt, which may be
useful as predictors to further select patients, are closely
related to the likelihood of imaging positivity. Schillaci et al.
[99] reported optimal thresholds for a positive 18F choline
PET-CT scan at PSA>2 ng/ml, PSAdt6mo, and PSAvelocity
>2 ng/ml/yr. Dusing et al. [101] reported that a PSA
threshold of 1.24 ng/ml or a PSA velocity of >1.32 ng/ml/
yr was an independent predictor of positive 11C acetate PET-
CT. Giovacchini et al. [74] reported that the detection rate of
11C choline in BCR after RP with PSA <1.5 ng/ml increased
from 21% to 50% if the patients also had PSAdt of <6 mo.
Castellucci et al. [71] observed very low detection rates of
11C choline PET-CT in patients with slow kinetics (3% of
patients with PSAdt >7.25 mo) and high detection rates in
patients with fast PSA kinetics (58% of patients with PSAdt
<7.25mo). Verburg et al. [121] showed that both higher PSA
levels and PSAdt were independent determinants of 68Ga
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lymph node metastases: 95% of patients with PSA2 ng/ml
and PSAdt < 6 mo had positive 68Ga PSMA-11 PET CT. In
contrast, Afshar-Oromieh et al. [112] found no associations
between 68Ga PSMA-11 PET-CT and PSAdt or PSA velocity in
a large retrospective study with multivariate analysis.
3.6. Diagnostic yield of PET-CT and ADT
Androgen deprivation therapy (ADT) is a systemic treat-
ment that is often used in relapsed patients to slow down
tumor progression. ADT causes reduction of tumor volume
and cell metabolism, which could consequently make them
more difficult to be detected with imaging. Some authors
have described a decrease in 11C choline or 18F choline
uptake after initiating hormonal therapy, but others found
no significant difference in the detection efficiency between
groups of patients with ADTand those not treated with ADT
[30,42,64,78,138]. Also for68Ga PSMA-11 PET-CT, the effect
of ADTon tumor detectability is complicated and appears to
depend on the size of the residual tumor, the time period
since the induction of ADT, and castration state of the
patient [112,116,139].
3.7. Influence of imaging on treatment choice
In many studies, significant changes in the planned
treatment are observed after imaging of patients with
BCR. Depending on the imaging findings, treatment may be
changed from palliative to curative intent, or patients may
have cancellation of planned therapy when imaging is
negative, or planned systemic treatment is converted to
targeted treatment when only a few metastatic lesions are
detected (oligometastasis). In the study of Mena et al. [129],
50% of patients had a change in treatment plan based on the
imaging findings on 18F-DCFBC PET-CT. Souvatzoglou et al.
[85] reported that 11C choline PET-CT detected abnormali-
ties outside the prostatic fossa in 13% of patients referred for
salvage RT after RP, affecting the extent of planning target
volume. Whole-body MRI studies also suggest that modern
imaging reveals the frequent observation of bone and node
metastases located outside the usual boundaries of salvage
pelvic lymph node dissection and of salvage RT fields [140].
Pretherapeutic imaging is gaining importance with the
emergence of individualized treatment strategies to replace
the use of palliative systematic therapies such as ADT for the
treatment of all patients with metastatic disease irrespec-
tive of disease extent, thereby decreasing the latter’s various
side effects. The profound impact of imaging in patients
with BCR in the early recurrence setting on treatment
strategy is thus quite clear, but it is unclear whether those
decisions are necessarily beneficial and result in improved
outcomes [123]. It would be of interest to investigate the
clinical outcomes in a randomized setting where imaging is
either offered or not offered to patients [123].
With the increasing use of imaging techniques such as
11C choline PET-CT and 68Ga PSMA-11 PET-CT, or wbMRI at
BCR, a substantially higher number of patients are being
detected with a low number of metastases, the so-called“oligometastatic disease” [141]. In the study of Graziani
et al. [77] using 11C choline PET-CT in patients with PSA
<1.16 ng/ml, oligometastatic diseasewas present in 22.7% of
patients and in 84.7% of positive scans. This should not
necessarily result in immediate palliative ADT but provides
an opportunity to investigate MDT in the form of targeted
surgery or high-dose “stereotactic body radiotherapy” as an
alternative [142–144]. Prospective studies in oligometa-
static PCa are needed to evaluate the effectiveness of MDT
compared with classical (systemic) treatments [145]. In-
deed, oligometastatic disease on modern imaging (PET-CT
or wbMRI) is only a “snapshot”, and it is not knownwhether
the disease will evolve to widespread metastases but have
simply been brought to attention at an early time point, or
whether this oligometastatic disease is unlikely to dissemi-
nate further. Oligometastatic PCa should therefore still be
considered as metastatic PCa, and ADT or observation with
deferred therapy has to be considered the standard of care
[146,147]. The role of imaging for the detection ofmetastatic
disease will likely increase in the coming years.
4. Discussion
This comprehensive systematic review summarizes the
available data on various imaging modalities that may be
used in patients with early recurrent PCa. Our systematic
literature search revealed wide variability in imaging
techniques such as CT, BS, TRUS, mpMRI, wbMRI, PET-CT,
and PET-MRI. Only a few studies compared two or more
imaging techniques in the same cohort of patients. Table 5
provides an overview of the most relevant findings of each
imaging technique.
The data show that the traditionally used imaging
techniques CT and BS are not sufficiently sensitive to
localize recurrence in the early recurrence setting. For the
detection of local recurrence, TRUS or mpMRI can be used;
however, at the lowest PSA levels, there are few data, only
after RP, showing awide range of positivity. TRUS or mpMRI
need to be combined with (PET)-CT (to assess regional or
distant relapse but also to have an incremental value in
facilitating the detection of local recurrence). An alternative
approach has been described, consisting of an “MRI-only”
approach combiningmpMRI for local relapse andwbMRI for
bone and node screening.
The vast majority of studies included in this systematic
review were performed with PET-CT using various tracers,
most predominantly 11C choline and recently PSMA-
targeted tracers, with the number of studies rapidly
growing in the last 5 yr [148]. At recurrent PSA levels
<0.5 ng/ml, detection rates up to 31.3% were reported using
11C choline PET-CTand up to 65.0% using 68Ga PSMA-11 PET-
CT. At recurrent PSA levels of <0.2 ng/ml, detection rates of
68Ga PSMA-11 PET-CT ranged from 11.3% to as high as 58.3%.
Our data support the superiority of PSMA-targeted tracers
over the older tracers in patients with early BCR, but there
are no studies directly comparing the performances in the
same patients. Although the reported diagnostic perfor-
mance of one imaging modality may be clearly higher than
that of another, a comparison using the literature alone has
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statistically significant superiority is also a risk because the
studies are considering extremely different and inhomoge-
neous populations, with differences in the PET equipment
and protocols used, absence of standardized image inter-
pretation data, and different types of lymphadenectomy
approaches (limited or extended), and interhospital and
interoperator skill and equipment factors, etc.), and it is
impossible to pool nonhomogeneous data to make a formal
statistical comparison. Moreover, extreme variability in the
performance of the same tracer was observed between
studies, probably for the same reasons.
The level of PSA at the time of imaging appeared to be
crucial: in studies comparing high and low PSAvalues at the
time of BCR, therewas a significantly lower detection rate at
lower PSA values. This issue is relevant for all radio-
pharmaceuticals used in PET-CT, and also for MRI or TRUS. It
is essential that clinical biomarkers of limited disease must
also be considered, such as time fromprimary tumor to BCR,
type of primary treatment, PSA level, PSAdt, PSA velocity,
etc. Currently, the goal is to identify BCR in patients after RP
at PSA level <0.5 ng/ml, but imaging the recurrence at the
lowest recurrent PSA values was most challenging for each
imaging technique. Some imaging techniques demonstrat-
ed very low detection rates, but this does not necessarily
imply a lack of clinical usefulness. A detection rate of, for
example, 16%may still be valuable for 16 out of 100 patients
given the data that next-generation imaging with PET often
changes clinical management of individual patients. How-
ever, since the most performant PET-CT scans are expensive
and not available in every hospital, it is necessary to know
which patients are most likely to benefit. It is a balance
between optimal accuracy and availability. For example, our
study showed that 11C choline PET-CT and 68Ga PSMA-11
PET-CT were better imaging modalities than BS, but BS has
the lowest price and highest availability. The current
European Association of Urology guidelines recommend
performing imaging only if the outcome influences subse-
quent treatment decisions. After RP, when the PSA level is
1 ng/ml, it is suggested to perform 68Ga PSMA-11 PET-CT if
available or choline PET-CT otherwise (weak strength
rating). In case of BCR after RT, it is recommended
performing mpMRI to localize abnormal areas and guide
biopsies in patients who are considered candidates for local
salvage therapy (strong strength rating). Additionally, it is
recommended to perform 68Ga PSMA-11 PET-CT if available,
or choline PET-CT otherwise, to rule out positive lymph
nodes or distant metastases in patients fit for curative
salvage treatment (strong strength rating).
Prospective studies are needed to establish the relative
performance of different tracers compared with various
other tracers or imaging methods. Owing to differences in
study design, PSA levels, reference standards, etc., the most
reliable comparison is best done by a trial in which both
imaging techniques are utilized in the same patient at the
samemoment and independently interpreted [49]. The two
tracers or imaging methods should be directly compared in
terms of overall positivity, negativity, on both at a per-
patient and at a per-site basis, sensitivity, specificity, PPV,and accuracy for both imaging techniques. Recently, the
Prostate CancerMolecular Imaging Standardized Evaluation
(PROMISE) was proposed to standardize image interpreta-
tion, which could result in more uniformity between future
studies on PET imaging [149].
Preferably the investigated tracer should, at least
theoretically, be available everywhere. For example, PSMA
has very limited access in only a few countries. Owing to
national differences in imaging guidelines and restrictions
in tracers, it is not feasible to give universal recommenda-
tions for the use of a tracer in clinical practice.
Our systematic review is limited by the quality of the
included studies. There was in general a poor methodologi-
cal quality of the studies in the available literature. The
majority of studies were retrospective and used a hetero-
geneous composite as a reference standard comprising
clinical follow-up with correlative alternative imaging (CT,
MR, BS), repeated PSA sampling, and histological examina-
tion in only a minority of patients.
Ideally, every lesion detected on imaging should be
confirmed by histology provided through image-guided
needle biopsies, but histopathology as the gold standard
was available in only a minority of studies. In a substantial
number of studies, a standard of reference to validate the
imaging results was completely lacking. The reasons why in
the recurrence setting histological proof of all lesions is
seldom possible are twofold. First, there are practical issues.
The location of the lesions is often deep within the pelvis
and consequently difficult to sample. If the number of
lesions is too high, it is not feasible to sample them all
individually. Second, there are also ethical issues regarding
the need to perform biopsies for research purposes only. If
the local recurrence is obvious based on imaging, histo-
pathological confirmation is usually not necessary. Biopsy is
invasive and may also fail to depict some tumors (false
negative rate). On the contrary, patients without any
suspicious lesion on imaging usually do not undergo biopsy.
Patients without evidence of metastatic disease are
therefore usually treated with RT to the prostate bed
without histological proof of local recurrence and are
validated by PSA decrease after subsequent therapy and/or
imaging follow-up.
A standard of reference is needed to correlate the
imaging results on a per-patient or per-lesion basis to
determine the exact number of true/false positives or true/
false negatives. In studies without histological confirmation
of the imaging findings, only “positivity” (sometimes
referred to as “detection rate”) of the imaging test was
reported. These studies consider all “positives” as “true
positives,” but the lack of histological correlation makes it
actually unclear as to the false positives. Many recent
studies on 68Ga PSMA-11 PET-CT refer to the study of Afshar-
Oromieh et al. [111] who demonstrated, in a subgroup of
42 patients with histological verification of lymph nodes,
very high specificity and no false positives. This paper is
often referred by other studies to explain why they waive a
standard of reference and consider the “positivity rate” to be
equal to the “detection rate.” In a studywith 11C choline PET-
CT, Nanni et al. [81] reported a difference of approximately
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the detection rate may significantly overestimate sensitivi-
ty. Consequently, because very few data are available for the
comparison of PET findings with histological assessment,
despite a high detection rate, the sensitivity and specificity
of PET-CT are still unknown for many tracers.
This limits not only the validity of the individual studies,
but also the validity of this systematic review. Nevertheless,
we decided to not exclude papers without a standard of
reference from the systematic literature research because in
the early BCR setting positivity may still have clinical value,
if one assumes that virtually all patients with PSA relapse
have recurrent disease somewhere and that there are
actually no true negative cases. Still, the correct or incorrect
location of the disease (local or distant) is a major issue and
a false positive distant disease precludes curative salvage
treatment. A lack of histological validation is thus a major
limitation of all the results presented in our systematic
review, and the reported imaging detection rates need to be
regarded with caution.
Despite a careful literature research, original articles
qualifying for inclusion may have been missed. Moreover,
we performed this systematic review in a rapidly evolving
field of research, and we know that relevant reports
appeared while we were completing this study.
5. Conclusions
The role of imaging in the setting of early recurrent PCa is to
demonstrate the localization of the relapse, which may be
local in the treated prostatic area, lymph nodes, or distant
metastasis. The detection rates depend on the level of the
PSA at the time of imaging. CT and BS are traditionally used,
but they are not sufficiently sensitive to localize recurrence
at low PSA values. Multiparametric MRI is a valuable
imagingmodality for the detection of local recurrence and is
often combined with PET-CT for the assessment of distant
disease. Newer techniques such as wbMRI, PET-MRI, or PET-
CT, especially with PSMA-directed tracers, allow for an all-
in-one approach, even at very low recurrent PSA values.
Imaging should be performed only if the outcome
influences subsequent treatment decisions.
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